Part V · Continuity · Estimated reading time 125 minutes · Prerequisites: Chapters 3, 16
In This Chapter
- Learning Objectives
- 27.1 Two Systems Built from One Plan
- 27.2 Male Anatomy
- 27.3 Male Physiology
- 27.4 Female Anatomy
- 27.5 Oogenesis and the Ovarian Cycle
- 27.6 Hormonal Control of the Female Cycle
- 27.7 The Uterine (Menstrual) Cycle
- 27.8 What Estrogen Does to the Rest of the Body
- 27.9 The Reproductive Lifespan
- 27.10 Advanced Topic · Selected Conditions as Physiology
- Chapter Summary
- Case File 27 · Resolution
- Systems Integration Case File · Entry 27
- Review
- Key Terms
27. The Reproductive System
Male and Female Anatomy and Physiology
Case File 27 — "Nothing Is Wrong With Your Pituitary"
Amara Osei is 45. Her periods, regular for thirty years, have been unpredictable for eighteen months — sometimes 24 days apart, sometimes 52, occasionally heavy enough to be alarming. She wakes at 03:00 drenched, six to eight times a day feels heat sweep up her chest and face, and sleeps badly even on the nights she is not working. She has assumed all of it was the heart attack, the medications, or the exhaustion.
Her cardiologist, reviewing a routine lipid panel, notices something else. Her cholesterol has been drifting in the wrong direction over exactly the same eighteen months.
| Measurement | Amara now | Three years ago | Reference |
|---|---|---|---|
| Cycle length | Irregular, 24–52 days | Regular, 27–29 days | Regular 21–35 days |
| FSH (early follicular) | 24 mIU/mL | not measured | 3–10 mIU/mL |
| LH (early follicular) | 14 mIU/mL | not measured | 2–10 mIU/mL |
| Estradiol (early follicular) | 38 pg/mL | not measured | 30–120 pg/mL |
| Anti-Müllerian hormone | 0.3 ng/mL | not measured | > 1.0 ng/mL at this age |
| Total cholesterol | 232 mg/dL | 198 mg/dL | < 200 |
| LDL cholesterol | 148 mg/dL | 118 mg/dL | < 100 |
| HDL cholesterol | 38 mg/dL | 46 mg/dL | > 50 (women) |
| Triglycerides | 244 mg/dL | 190 mg/dL | < 150 |
| Vasomotor symptoms | 6–8 flushes/day, night sweats | none | — |
Her cardiologist writes one sentence in the note: "Cardiovascular risk profile has changed with hormonal status; this is not incidental."
Meanwhile her daughter Nia, 24, a marathon runner and physical therapy student, has been logging her own data for a training project. She has noticed that two variables move together, every month, on a schedule.
| Nia's measurement | Days 3–12 | Days 17–26 |
|---|---|---|
| Resting heart rate on waking | 52 beats/min | 57 beats/min |
| Basal body temperature on waking | 36.4 °C (97.5 °F) | 36.8 °C (98.2 °F) |
Three questions to hold on to.
- What does estrogen actually do to blood vessels and to blood lipids — and why should losing it change a woman's cardiovascular risk?
- Why does Nia's core temperature shift with her cycle, and by how much? What is the mechanism, and why does her resting heart rate move with it?
- Amara's FSH is 24 mIU/mL, well above the reference range. Her pituitary is normal. What is FSH responding to?
Learning Objectives
By the end of this chapter you should be able to:
- Name the four components shared by both reproductive systems and give the male and female version of each.
- Describe the bipotential gonad, the two duct systems, and the roles of SRY, anti-Müllerian hormone, and testosterone in sexual differentiation; complete a table of homologous structures.
- Describe the gross and microscopic anatomy of the testis, and explain the scrotum, dartos, cremaster, and pampiniform plexus as a single thermoregulatory apparatus.
- Trace a sperm cell from seminiferous tubule to external urethral orifice, naming every duct and accessory gland and its secretion.
- Explain erection and ejaculation as separate events with different innervation, and describe the nitric oxide mechanism.
- Sequence spermatogenesis from spermatogonium to spermatozoon, distinguish it from spermiogenesis, and state the timeline.
- Explain the blood-testis barrier and list four functions of sustentacular (Sertoli) cells.
- Diagram the male hypothalamic-pituitary-gonadal axis, naming the two feedback signals and what each controls.
- List testosterone's actions and identify which require conversion to DHT or to estradiol.
- Describe female internal and external anatomy, including the uterine layers and the difference between spiral and straight arteries, and explain menstruation mechanically from that difference.
- Trace oogenesis from primordial germ cell to ovum, explain the two meiotic arrests, and account for the decline of the oocyte pool from 7 million to 400 ovulations.
- Sequence follicular development from primordial follicle to corpus albicans and explain the two-cell, two-gonadotropin model of ovarian steroid synthesis.
- Plot FSH, LH, estradiol, and progesterone across 28 days and explain how estrogen's feedback switches from negative to positive to produce the LH surge.
- Synchronize the uterine cycle with the ovarian cycle and explain the basal body temperature rise as a set-point shift caused by progesterone.
- List estrogen's non-reproductive actions on bone, endothelium, lipids, fat distribution, and brain, and predict the consequences of losing each.
- Explain perimenopause as loss of ovarian follicular reserve and derive the rise in FSH from negative feedback disinhibition.
- Describe the hormonal trigger for puberty and the sequence of secondary sexual characteristics in both sexes.
- Explain polycystic ovary syndrome, endometriosis, and benign prostatic hyperplasia mechanistically, and map the major contraceptive methods onto the cycle figure.
27.1 Two Systems Built from One Plan
Every other organ system in this book maintains the individual. This one does not. It maintains the species, at some cost to the individual, and that difference in purpose shows up everywhere in its design.
Both systems have the same four components:
| Component | Male | Female |
|---|---|---|
| Gonads — make gametes and hormones | Testes | Ovaries |
| Ducts — transport gametes | Epididymis, ductus deferens, ejaculatory duct, urethra | Uterine tubes, uterus, vagina |
| Accessory glands — support gametes | Seminal vesicles, prostate, bulbourethral glands | Greater and lesser vestibular glands; also the cervix and the uterine glands |
| External genitalia | Penis, scrotum | Vulva: mons, labia, clitoris, vestibule |
Thread 1 · Structure Determines Function
The two gametes are the most extreme illustration of structure-function matching in the body, because they solve two halves of one problem.
A spermatozoon is about 60 µm long and almost all of it is machinery for travel: a condensed nucleus with an enzyme-filled cap in front, a helix of mitochondria behind it, and a flagellum. It has jettisoned nearly all its cytoplasm. It carries genetic information and nothing else, because it must move.
An oocyte is about 120 µm across — the largest human cell, visible without a microscope — and almost all of it is cytoplasm: maternal mRNA, ribosomes, mitochondria, and stored nutrients. It does not move at all; it is carried. It supplies everything the first days of an embryo will need before the embryonic genome switches on.
One gamete is a delivery vehicle; the other is a fully provisioned workshop. Every downstream difference between the two systems — how many gametes are made, how continuously, how they are transported, and what happens to the parent afterwards — follows from that one asymmetry.
A note on terminology
The anatomical and physiological terms in this chapter describe body structures and their functions. Terms such as "male" and "female" are used here in their biological sense — referring to the reproductive anatomy a person has and the sex typically assigned at birth on the basis of external genitalia — and are distinct from gender identity, a person's internal sense of their own gender. The two do not always correspond.
Clinically, the operative question is never a label but an organ inventory: a person who has a cervix needs cervical screening, and a person who has a prostate needs prostate care, regardless of how they identify or what their records say. Use precise anatomical language and ask what organs are present. That is both more respectful and more accurate.
The bipotential gonad: one embryo, two possible outcomes
Every human embryo spends its first six weeks capable of becoming either. It has an indifferent gonad and — remarkably — both duct systems, one of which will be discarded.
SEXUAL DIFFERENTIATION — one starting point, two paths
WEEK 5–6 · THE INDIFFERENT (BIPOTENTIAL) STAGE
┌─────────────────────────────────────────────────────────────────┐
│ GENITAL RIDGE (bipotential gonad) │
│ ▲ colonized by PRIMORDIAL GERM CELLS that migrated from │
│ the yolk sac along the hindgut │
│ │
│ BOTH duct systems present, side by side: │
│ MESONEPHRIC (WOLFFIAN) duct ──── the male plan │
│ PARAMESONEPHRIC (MÜLLERIAN) duct ── the female plan │
│ │
│ INDIFFERENT EXTERNAL GENITALIA: │
│ genital tubercle · urogenital folds · labioscrotal swellings │
└──────────────────────────┬──────────────────────────────────────┘
│
┌───────────────────┴────────────────────┐
│ SRY PRESENT (Y chromosome) │ SRY ABSENT
▼ ▼
╔══════════════════════════╗ ╔═══════════════════════════╗
║ SRY → SOX9 → TESTIS ║ ║ WNT4 / RSPO1 / FOXL2 ║
║ (week 6–7) ║ ║ → OVARY ║
╚═════════╤════════════════╝ ║ (NOT a passive default — ║
│ ║ an active program) ║
┌──────┴───────┐ ╚═══════════╤═══════════════╝
▼ ▼ │
SERTOLI CELLS LEYDIG CELLS │ no AMH
secrete AMH secrete TESTOSTERONE │ no testosterone
│ │ │
▼ ▼ ▼
MÜLLERIAN WOLFFIAN ducts MÜLLERIAN ducts PERSIST
ducts STABILIZED → uterine tubes, uterus,
REGRESS → epididymis cervix, upper vagina
→ ductus deferens
→ seminal vesicle WOLFFIAN ducts REGRESS
→ ejaculatory duct
│
testosterone ──5α-reductase──► DHT
│ │
▼ ▼
(internal ducts) EXTERNAL GENITALIA + PROSTATE
══════════════════════════════════════════════════════════════════
THE ASYMMETRY WORTH REMEMBERING:
Male development requires TWO ACTIVE HORMONAL SIGNALS — AMH to
destroy one duct system and testosterone to save the other.
Remove the fetal testis and the embryo develops a female tract
REGARDLESS of chromosomes. The male pathway is the one that must
be actively built; that is why it has more ways to go wrong.
Figure 27.1 — Sexual differentiation from the bipotential gonad.
Described: A branching diagram beginning at weeks five to six with the indifferent or bipotential stage. A genital ridge forms the bipotential gonad and is colonized by primordial germ cells that have migrated from the yolk sac along the hindgut. Both duct systems are present side by side: the mesonephric or Wolffian duct, which represents the male plan, and the paramesonephric or Müllerian duct, which represents the female plan. The external genitalia are also indifferent, consisting of a genital tubercle, urogenital folds, and labioscrotal swellings. The diagram then branches. On the left, when SRY on the Y chromosome is present, SRY activates SOX9 and the gonad becomes a testis at weeks six to seven. The testis produces two cell types with two products: Sertoli cells secrete anti-Müllerian hormone, which causes the Müllerian ducts to regress, and Leydig cells secrete testosterone, which stabilizes the Wolffian ducts so that they become the epididymis, ductus deferens, seminal vesicle, and ejaculatory duct. Testosterone is further converted by five-alpha-reductase to dihydrotestosterone, which builds the external genitalia and the prostate. On the right, when SRY is absent, an active genetic program involving WNT4, RSPO1, and FOXL2 produces an ovary — this is emphasized as an active program rather than a passive default. Without anti-Müllerian hormone the Müllerian ducts persist and become the uterine tubes, uterus, cervix, and upper vagina; without testosterone the Wolffian ducts regress. A closing note states the key asymmetry: male development requires two active hormonal signals, one to destroy a duct system and one to save the other, so that removing the fetal testis produces a female tract regardless of chromosomes — the male pathway must be actively built, which is why it has more ways to go wrong.
Homologous structures
Because both sexes start from the same parts, most adult structures have a counterpart. Learning the table once saves a great deal of memorization later, and it explains several clinical oddities.
| Indifferent structure | Male derivative | Female derivative |
|---|---|---|
| Bipotential gonad | Testis | Ovary |
| Genital tubercle | Glans penis | Glans clitoris |
| Urogenital folds | Ventral shaft of penis, spongy urethra | Labia minora |
| Labioscrotal swellings | Scrotum | Labia majora |
| Gubernaculum | Gubernaculum testis | Ovarian ligament and round ligament of the uterus |
| Mesonephric (Wolffian) duct | Epididymis, ductus deferens, seminal vesicle, ejaculatory duct | Regresses (Gartner's duct remnants) |
| Paramesonephric (Müllerian) duct | Regresses (appendix testis, prostatic utricle) | Uterine tubes, uterus, cervix, upper vagina |
| Urogenital sinus | Prostate, bulbourethral glands, prostatic and membranous urethra | Lower vagina, urethra, greater vestibular (Bartholin) glands |
Two payoffs. The round ligament of the uterus is the female gubernaculum, and it takes the same path a testis would — through the inguinal canal to the labium majus — which is why inguinal hernias occur in women along that track. And the prostatic utricle, a small blind pouch in the male prostatic urethra, is a Müllerian remnant: a vestigial uterus, a few millimetres long, inside every prostate.
Development · Descent of the Testis, and Why an Undescended One Matters
The testis forms high on the posterior abdominal wall, at roughly the level of the future kidney, and must travel to the scrotum. It does so in two phases, guided by the gubernaculum, a fibromuscular cord anchoring the lower pole of the testis to the labioscrotal swelling.
The transabdominal phase (weeks 8–15) moves the testis to the deep inguinal ring and depends on insulin-like factor 3 from Leydig cells. The inguinoscrotal phase (weeks 25–35) draws it through the inguinal canal into the scrotum and is androgen-dependent. As it passes, it drags a diverticulum of peritoneum with it — the processus vaginalis — which normally obliterates, leaving only the double-layered tunica vaginalis around the testis. That tunica is a serous membrane, with visceral and parietal layers and a potential space between them, exactly like the pleura and pericardium of Chapter 1; when it fills with fluid, the result is a hydrocele.
Two consequences follow.
Failure of obliteration leaves a patent processus vaginalis — a ready-made tunnel from the peritoneal cavity to the scrotum, and the anatomical basis of an indirect inguinal hernia.
Failure of descent is cryptorchidism, present in about 3% of term and 30% of preterm male newborns; most descend spontaneously by three to six months. If the testis remains in the abdomen or inguinal canal, it sits at core body temperature (37 °C) instead of at 34 °C. Two things follow directly from §27.2's thermoregulation argument: spermatogenesis fails progressively, with germ cell loss measurable from the second year of life, and the risk of testicular germ cell tumour rises several-fold. Surgical placement in the scrotum — orchidopexy — before 12–18 months improves fertility outcomes and, importantly, makes the testis examinable, because a tumour in an abdominal testis is found late.
Note what the sidebar has just done: it derived a fertility problem and a cancer risk from a temperature, and derived the temperature from a journey.
27.2 Male Anatomy
The testes and the temperature problem
Each testis is about 4 × 2.5 cm and weighs 10–15 g. It is wrapped in a tough fibrous capsule, the tunica albuginea, which sends septa inward to divide the organ into 250–300 lobules. Each lobule contains one to four tightly coiled seminiferous tubules — roughly 250 metres of tubule in each testis, packed into something the size of a small plum. Between the tubules lie the interstitial (Leydig) cells, which make testosterone.
Sperm production requires a temperature 2–3 °C below core, around 34 °C. Above that, spermatogenesis fails. Three structures maintain the difference, and together they are one of the best structure-function arguments in the body.
Predict This
Almost every other organ in the body is kept inside, at 37 °C, where it is warm and protected. The testes are carried outside the body wall in a thin, unprotected sac, at 34 °C — an arrangement that is mechanically dangerous and metabolically expensive to maintain.
Before reading on: commit to an answer. What must be true about the biochemistry of sperm production for that trade to be worth making?
(Answer: some step of spermatogenesis — the DNA repair and chromatin-remodeling machinery of meiosis and spermiogenesis is the prime suspect — has a temperature optimum below core temperature and fails above it. The cost of exposing the gonad is smaller than the cost of producing damaged gametes. The experiment has been run: an undescended testis, held at 37 °C, loses germ cells progressively from the second year of life while its Leydig cells — which make testosterone and are not temperature-sensitive — keep working. Temperature costs the gametes and spares the hormone.)
Thread 1 · Structure Determines Function — Three Solutions to One Thermal Problem
1 · The dartos muscle. A sheet of smooth muscle in the superficial fascia of the scrotum. When it contracts, the scrotal skin wrinkles, reducing surface area and therefore radiative and convective heat loss; when it relaxes, the scrotum hangs loose and flat, maximizing the surface available for cooling. A variable radiator.
2 · The cremaster muscle. Skeletal muscle derived from the internal oblique, wrapping the spermatic cord. Contraction pulls the testes up toward the warm body wall; relaxation lets them descend away from it. A variable distance. (Stroking the medial thigh elicits the cremasteric reflex — testable at the bedside, and its absence is one sign of testicular torsion.)
3 · The pampiniform plexus — a countercurrent heat exchanger. This is the elegant one. The testicular artery descends through the spermatic cord carrying blood at 37 °C. Around it, a dense network of veins ascends carrying blood that has been cooled in the scrotum to about 33 °C. Heat passes from the warm descending artery into the cool ascending veins before the arterial blood ever reaches the testis, so blood arrives at roughly scrotal temperature rather than core temperature.
You have met this exact physics before. It is the countercurrent exchanger of the vasa recta (Chapter 26, §26.6) — hairpin geometry, opposite flow directions, passive exchange along the whole length, no energy expended. One arrangement, two organs, two entirely different cargoes: the kidney exchanges solute to protect an osmotic gradient, the testis exchanges heat to protect an enzyme. When you meet a countercurrent arrangement anywhere in biology, ask what is being conserved.
The clinical proof that the plexus matters is the varicocele — dilated, incompetent pampiniform veins, present in about 15% of men and 40% of men presenting with infertility. Blood pools, the heat exchange fails, scrotal temperature rises by 1–2 °C, and sperm count and motility fall. Roughly 85–90% are left-sided, for a purely anatomical reason: the left testicular vein drains at a right angle into the left renal vein, against a higher pressure, while the right drains obliquely into the inferior vena cava. Varicocele is the commonest surgically correctable cause of male infertility.
The duct system
| Structure | Length | Epithelium | Function |
|---|---|---|---|
| Seminiferous tubule | ~250 m total | Stratified: germ cells + Sertoli cells | Spermatogenesis |
| Rete testis → efferent ductules | Short | Cuboidal, some ciliated | Collect sperm; reabsorb fluid |
| Epididymis | ~6 m coiled into 4 cm | Pseudostratified columnar with stereocilia (long microvilli) | Maturation — sperm gain motility and the ability to bind the oocyte, over 12–20 days; storage in the tail |
| Ductus (vas) deferens | ~45 cm | Pseudostratified columnar | Rapid propulsion by three thick smooth muscle layers; site of vasectomy |
| Ejaculatory duct | ~2 cm | Simple columnar | Passes through the prostate to the prostatic urethra |
| Urethra | 18–20 cm | Varies by region | Shared final path for urine and semen |
Sperm leaving the seminiferous tubule cannot swim and cannot fertilize. Both capacities are acquired during the passage through the epididymis, which is why the organ is 6 metres long: it is a maturation delay line. The stereocilia are not motile — they are absorptive microvilli that reclaim the large volume of fluid secreted by the tubules.
The spermatic cord carries the ductus deferens, the testicular artery, the pampiniform plexus, lymphatics, autonomic nerves, and the cremaster through the inguinal canal. Because the whole bundle is suspended, it can twist: testicular torsion strangles the testicular artery and causes infarction within about six hours, which is why sudden severe testicular pain is a surgical emergency rather than an outpatient problem.
The accessory glands
Sperm are about 5% of the volume of semen. The other 95% is manufactured by three glands, and each contributes something the sperm cannot make for itself.
| Gland | Share of volume | Secretion | Why |
|---|---|---|---|
| Seminal vesicles (paired) | 60–70% | Alkaline fluid with fructose, prostaglandins, clotting protein (semenogelin), vitamin C | Fructose is the sperm's fuel; prostaglandins stimulate contractions of the female tract; the clotting protein forms a temporary coagulum that holds semen near the cervix |
| Prostate | 25–30% | Milky, slightly acidic fluid with citrate, zinc, and prostate-specific antigen (PSA) | PSA is a protease that liquefies the coagulum 15–30 minutes later, releasing the sperm |
| Bulbourethral (Cowper's) | < 1% | Clear alkaline mucus, released before ejaculation | Neutralizes acidic urine residue in the urethra and lubricates |
Semen is 2–5 mL, pH 7.2–8.0, containing 15 million or more sperm per millilitre. The alkalinity is functional: the vagina is maintained at pH 3.5–4.5 by lactobacilli (§27.4), which is hostile to sperm, and semen buffers it for long enough to allow passage. Note the coagulate-then-liquefy sequence — two glands, two enzymes, a deliberate 20-minute delay that keeps sperm concentrated at the cervix before releasing them.
The penis
Three cylinders of erectile tissue run through the shaft: the paired corpora cavernosa dorsally, and the single corpus spongiosum ventrally, which surrounds the spongy urethra and expands distally as the glans. Each corpus cavernosum is wrapped in a tough, relatively inextensible tunica albuginea; the corpus spongiosum's covering is thinner and more elastic.
That difference is not decorative. During erection the cavernosa become rigid because their stiff tunica lets pressure build; the spongiosum stays deliberately less rigid, so that the urethra running through it is not occluded and semen can still pass. Two tissues with the same function and different mechanical properties, because one of them has a tube inside it.
Erection is a vascular event under parasympathetic control (pelvic splanchnic nerves, S2–S4). Nitric oxide is released from nonadrenergic-noncholinergic nerve terminals and from endothelium; it activates guanylate cyclase in vascular smooth muscle; cGMP rises; the helicine arteries dilate and the trabecular smooth muscle relaxes. Sinusoids fill with blood, and as they expand they compress the subtunical venules against the rigid tunica albuginea, occluding venous outflow. Inflow up, outflow shut, pressure rises: rigidity.
Emission and ejaculation are separate and sympathetic and somatic. Emission (L1–L2) moves sperm and glandular secretions into the prostatic urethra and simultaneously contracts the internal urethral sphincter, preventing retrograde flow into the bladder. Ejaculation is rhythmic somatic contraction of the bulbospongiosus and ischiocavernosus via the pudendal nerve. The classical mnemonic — point and shoot, parasympathetic then sympathetic — is crude but correct, and it explains why drugs and nerve injuries can abolish one while sparing the other.
Clinical Connection · Erectile Dysfunction Is an Endothelial Disease
Erection depends on nitric oxide made by endothelium. So does flow-mediated dilation in the coronary and brachial arteries (Chapter 19). It is the same molecule, the same enzyme, and the same vascular biology — which means that anything that damages endothelium damages both.
The clinical consequence is striking and well documented: erectile dysfunction of vascular origin typically precedes a coronary event by three to five years. The reason is mechanical rather than mysterious. Penile arteries are roughly 1–2 mm in diameter; coronary arteries are 3–4 mm. The same degree of endothelial dysfunction and plaque burden narrows the smaller vessel to a symptom-producing degree earlier. ED is an early-warning system with a small lumen.
This is why a new complaint of ED in a man over 40 warrants a cardiovascular risk assessment rather than a prescription alone, and it is why the risk factors are identical: diabetes, hypertension, smoking, dyslipidemia, obesity, and sleep apnea — the entire list from Amara's own chart.
PDE5 inhibitors (sildenafil, tadalafil) exploit the mechanism directly. Phosphodiesterase-5 breaks down cGMP; blocking it lets cGMP accumulate, amplifying whatever nitric oxide signal is present. Note the implication: these drugs amplify a signal, they do not create one, which is why sexual stimulation is still required for them to work. And note the absolute contraindication that follows from the same pathway — nitrates also act by donating nitric oxide, so combining them with a PDE5 inhibitor drives cGMP high enough to cause catastrophic hypotension. That interaction is a piece of pure signal-transduction reasoning, and it appears on Amara's own medication warning list because she takes a nitrate.
MALE REPRODUCTIVE TRACT — sagittal (midline) section
╱ sacrum
URINARY BLADDER ╱
╭──────────────╮ ╱ ┌─────────────────────────────┐
│ │ ╱ │ SEMINAL VESICLE (paired) │
│ urine │─────╱────────────┤ 60–70% of semen volume │
│ │ ╱ ╭───────╮ │ fructose · prostaglandins · │
╰───────┬──────╯ ╱ │SEMINAL│◄─┤ clotting protein · alkaline │
│ ╱ │VESICLE│ └─────────────────────────────┘
╔════╪═════════╪════╪═══════╪══════════════╗
║ internal urethral sphincter (smooth m.) ║ RECTUM
║ ╭──────────────────────╮ ║ │
║ │ PROSTATE │◄── EJACULATORY ║ │
║ │ 25–30% of volume │ DUCT (2 cm) ║ ▼
║ │ citrate · zinc · │ ║
║ │ PSA (liquefies the │ ▲ ductus deferens joins the
║ │ coagulum) │ │ seminal vesicle duct HERE
║ ╰──────────┬───────────╯ │ ║
║ PROSTATIC URETHRA │ ampulla of ductus ║
╚═══════════╪════════════════╪═══════════════════════╝
│ │
BULBOURETHRAL ○───► MEMBRANOUS │ ← external urethral sphincter
(COWPER'S) URETHRA │ (SKELETAL muscle, voluntary,
< 1%, pre-ejaculate │ pudendal n., S2–S4)
alkaline mucus │
│ │ DUCTUS (VAS) DEFERENS, 45 cm
┌──────────────┴────────────┐ │ ▲ ascends in the SPERMATIC CORD
│ PENIS — cross-section: │ │ │ through the INGUINAL CANAL
│ ○ ○ corpora cavernosa │ │ │
│ (paired, DORSAL; │ │ │ ★ VASECTOMY cuts here
│ stiff tunica → │ │ │
│ rigidity) │ │ │
│ ○ corpus spongiosum │ │ │
│ (single, VENTRAL; │───┴──┘
│ thinner tunica → │ ╭──────────────────────╮
│ stays compliant so │ │ EPIDIDYMIS (6 m │
│ the urethra stays │ │ coiled into 4 cm) │
│ OPEN) │ │ head · body · TAIL │
│ ↳ expands as GLANS │ │ MATURATION 12–20 d │
└────────────┬──────────────┘ │ + STORAGE │
│ ╰───────────┬──────────╯
SPONGY (PENILE) URETHRA ╭─────────┴─────────╮
│ │ TESTIS │
▼ │ seminiferous │
external urethral orifice │ tubules (~250 m) │
│ + LEYDIG cells │
SCROTUM: dartos (smooth m.) + ╰───────────────────╯
cremaster (skeletal m.) +
PAMPINIFORM PLEXUS (countercurrent heat exchanger) hold the
testes at ~34 °C, 2–3 °C BELOW core temperature.
THE PATH OF A SPERM CELL, IN ORDER:
seminiferous tubule → rete testis → efferent ductules → EPIDIDYMIS
→ DUCTUS DEFERENS → ampulla → EJACULATORY DUCT → prostatic urethra
→ membranous urethra → spongy urethra → out
Figure 27.2 — The male reproductive tract in sagittal section, with the path of a sperm cell.
Described: A midline sagittal view of the male pelvis and perineum. The urinary bladder lies anteriorly, with the paired seminal vesicles behind and below it; the seminal vesicles contribute sixty to seventy percent of semen volume, supplying fructose, prostaglandins, a clotting protein, and alkaline fluid. Beneath the bladder neck sits the internal urethral sphincter of smooth muscle and then the prostate, which contributes twenty-five to thirty percent of semen volume including citrate, zinc, and prostate-specific antigen, the protease that later liquefies the semen coagulum. The ductus deferens widens into an ampulla and joins the seminal vesicle duct to form the two- centimetre ejaculatory duct, which passes through the prostate into the prostatic urethra. Below the prostate the urethra becomes the membranous segment, encircled by the external urethral sphincter of skeletal muscle supplied by the pudendal nerve from S2 to S4; the paired bulbourethral or Cowper's glands add less than one percent of volume as alkaline pre-ejaculatory mucus. The urethra then runs through the penis as the spongy urethra to the external urethral orifice. In cross-section the penis contains two dorsal corpora cavernosa, whose stiff tunica albuginea allows rigidity, and a single ventral corpus spongiosum with a thinner, more compliant covering so that the urethra inside it stays open; the spongiosum expands distally as the glans. Posteriorly lies the rectum. Below, the scrotum contains the testis with its roughly 250 metres of seminiferous tubules and its Leydig cells, and the epididymis, six metres of duct coiled into four centimetres, where sperm mature over twelve to twenty days and are stored in the tail. The ductus deferens, 45 centimetres long, ascends from the epididymis within the spermatic cord through the inguinal canal; vasectomy interrupts it here. The dartos smooth muscle, the cremaster skeletal muscle, and the pampiniform venous plexus acting as a countercurrent heat exchanger hold the testes near 34 degrees Celsius, two to three degrees below core temperature. The path of a sperm cell is listed in order: seminiferous tubule, rete testis, efferent ductules, epididymis, ductus deferens, ampulla, ejaculatory duct, prostatic urethra, membranous urethra, spongy urethra, and out.
27.3 Male Physiology
Spermatogenesis
Spermatogenesis begins at puberty and continues, with declining efficiency, for life. It produces roughly 300 million sperm per day, and each one takes 64–72 days to make.
THE SEMINIFEROUS TUBULE IN CROSS-SECTION
read from the OUTSIDE IN — each step inward is a step forward in time
══════ BASEMENT MEMBRANE / MYOID CELLS ════════════════════════════
● SPERMATOGONIUM (2n, 46) ┌──────────────────────────┐
type A dark = reserve stem cell │ BASAL COMPARTMENT │
type A pale = renewing │ outside the barrier; │
type B = committed │ in contact with blood │
│ MITOSIS └──────────────────────────┘
▼
● PRIMARY SPERMATOCYTE (2n, 4C) ═══ BLOOD-TESTIS BARRIER ═══
enters MEIOSIS I; prophase I (tight junctions between
lasts ~22 days — the longest adjacent SERTOLI cells)
stage, and why a tubule cross- ┌──────────────────────────┐
section is full of them │ ADLUMINAL COMPARTMENT │
│ MEIOSIS I completes │ immunologically │
▼ │ privileged; no blood │
● ● SECONDARY SPERMATOCYTES (n, 2C) │ contact │
short-lived (~8 hours) — rarely └──────────────────────────┘
seen on a slide
│ MEIOSIS II
▼
● ● ● ● SPERMATIDS (n, 1C) — four from one primary spermatocyte
│
│ SPERMIOGENESIS — no further division; a RESHAPING
│ · Golgi → ACROSOME cap over the nucleus
│ · centriole → FLAGELLUM
│ · mitochondria → helix around the MIDPIECE
│ · histones → PROTAMINES; nucleus condenses
│ · surplus cytoplasm shed as a RESIDUAL BODY
│ (phagocytosed by the Sertoli cell)
▼
►►► SPERMATOZOON released into the LUMEN (spermiation)
══════ LUMEN ══════════════════════════════════════════════════════
immotile at this point; gains motility in the EPIDIDYMIS
THE SERTOLI (SUSTENTACULAR) CELL spans the full thickness:
╱│ basement membrane ──────────────────────► lumen │╲
│ · forms the BLOOD-TESTIS BARRIER (tight junctions)
│ · NOURISHES all germ cells (they have no blood contact)
│ · PHAGOCYTOSES residual bodies and failed germ cells
│ · secretes ANDROGEN-BINDING PROTEIN → intratubular
│ testosterone ~100× plasma concentration
│ · secretes INHIBIN B → selective negative feedback on FSH
│ · secreted AMH in the fetus (Figure 27.1)
TIMELINE: spermatogonium ──64–72 days──► spermatozoon in lumen
+ 12–20 days in the epididymis before it can swim
Figure 27.3 — The seminiferous tubule in cross-section, with spermatogenesis arranged from basement membrane to lumen.
Described: A cross-section through a seminiferous tubule, read from the outside inward, in which each step toward the lumen is also a step forward in developmental time. At the basement membrane, surrounded by myoid cells, sit the spermatogonia, diploid cells with 46 chromosomes, existing as type A dark reserve stem cells, type A pale renewing cells, and committed type B cells. These divide by mitosis to produce primary spermatocytes, which enter meiosis one; prophase of meiosis one lasts about 22 days, the longest stage, which is why primary spermatocytes dominate any tubule section. A blood-testis barrier formed by tight junctions between adjacent Sertoli cells divides the tubule into a basal compartment outside the barrier, which is in contact with blood, and an adluminal compartment inside it, which is immunologically privileged and has no blood contact. Completion of meiosis one produces two short-lived secondary spermatocytes, haploid with two chromatid copies, which survive only about eight hours and are rarely seen on a slide. Meiosis two produces four spermatids, haploid with one copy each, from every original primary spermatocyte. Spermiogenesis then reshapes each spermatid without further division: the Golgi apparatus forms an acrosome cap over the nucleus, a centriole forms the flagellum, mitochondria form a helix around the midpiece, protamines replace histones so the nucleus condenses, and surplus cytoplasm is shed as a residual body that the Sertoli cell phagocytoses. The finished spermatozoon is released into the lumen in a process called spermiation, still immotile, and gains motility later in the epididymis. The Sertoli or sustentacular cell spans the full thickness from basement membrane to lumen and performs six jobs: forming the blood-testis barrier, nourishing all germ cells, which have no blood supply of their own, phagocytosing residual bodies and failed germ cells, secreting androgen-binding protein that keeps intratubular testosterone about one hundred times plasma concentration, secreting inhibin B as selective negative feedback on FSH, and secreting anti-Müllerian hormone in the fetus. The timeline given is 64 to 72 days from spermatogonium to spermatozoon in the lumen, plus a further 12 to 20 days in the epididymis before the cell can swim.
Three things about that figure repay attention.
The geometry is a timeline. Germ cells begin at the basement membrane and migrate toward the lumen as they mature, so a single cross-section shows every stage of the process arranged in space. Nowhere else in the body can you read a two-month developmental sequence off one slide.
The blood-testis barrier solves an immunological problem. Cells that complete meiosis express surface proteins that did not exist when the immune system learned self-tolerance in fetal life. To the immune system they are foreign. Sertoli tight junctions seal them into an adluminal compartment with no blood contact — and, crucially, the junctions open and reform behind each ascending spermatocyte, like a lock in a canal. Breach the barrier by trauma, infection (mumps orchitis), or vasectomy, and antisperm antibodies may develop, which is one reason vasectomy reversal does not always restore fertility even when the plumbing is reconnected.
Spermiogenesis is not a division. It is a demolition and rebuild: a round cell with normal organelles becomes a streamlined missile, discarding most of its cytoplasm and replacing its histones with protamines to pack the DNA into a volume small enough to travel. It is the most extreme cellular remodeling in the body.
The male hypothalamic-pituitary-gonadal axis
The male axis has one distinctive feature worth stating up front: it is a pure negative feedback system, and it runs at a steady state. There is no cycle, no surge, and no switch — which is exactly the comparison that makes §27.6 vivid.
- The hypothalamus releases GnRH in pulses roughly every 90–120 minutes. Pulsatility is essential; continuous GnRH desensitizes the pituitary, which is the mechanism of GnRH agonist drugs used to suppress the axis.
- LH acts on Leydig cells → testosterone.
- FSH acts on Sertoli cells → androgen-binding protein, inhibin B, and support for spermatogenesis.
- Testosterone feeds back to inhibit both GnRH and LH.
- Inhibin B feeds back to inhibit FSH selectively.
Two feedback signals for two outputs. Testosterone reports on the endocrine arm; inhibin B reports on the gamete-producing arm. That separation is what allows a man to have normal testosterone and azoospermia at the same time, with an isolated high FSH as the only clue — the same reasoning that will explain Amara's FSH in §27.8.
Testosterone's actions, and the two conversions
Testosterone is a prohormone as much as a hormone. Some of its effects are its own; others require conversion by one of two enzymes.
| Target | Effect | Requires conversion? |
|---|---|---|
| Fetal Wolffian ducts | Epididymis, ductus deferens, seminal vesicle | No — testosterone directly |
| External genitalia, prostate, hair follicles | Virilization; prostatic growth; male-pattern hair | Yes — DHT, via 5α-reductase |
| Bone: growth spurt, then epiphyseal closure | Linear growth then its termination | Yes — estradiol, via aromatase |
| Skeletal muscle | Increased protein synthesis and mass | No |
| Bone density | Maintenance; loss causes osteoporosis in men too | Both pathways |
| Bone marrow | Increased erythropoietin and red cell mass (hence higher hematocrit) | No |
| Larynx, sebaceous glands, body hair | Voice deepening, acne, hair pattern | Largely DHT |
| Brain | Libido, aggression, spatial cognition | Both |
| Seminiferous tubules | Supports spermatogenesis (paracrine, at ~100× plasma concentration) | No |
The estradiol row surprises everyone and matters clinically. Male bones close their epiphyses in response to estrogen, not androgen — proven by rare men with aromatase deficiency or non-functional estrogen receptors, who continue growing into their thirties and develop osteoporosis. It is the reason aromatase inhibitors are used cautiously in adolescents, and it connects directly to Chapter 6: estrogen is the principal bone-preserving steroid in both sexes.
The DHT row explains two drugs. Finasteride inhibits 5α-reductase, shrinking the prostate and slowing male-pattern hair loss, while leaving muscle and libido largely intact because those depend on testosterone itself.
Exercise & Sport · Anabolic Steroids and the Male Athlete Triad
Exogenous androgens shut down the axis. Supraphysiological testosterone or its analogues suppress GnRH, and therefore LH and FSH. Four consequences follow directly from the axis just described (and drawn in full in Figure 27.7):
- Testicular atrophy and azoospermia. Intratubular testosterone depends on LH acting on Leydig cells inside the testis, and no amount of injected testosterone reproduces the 100-fold intratubular concentration that androgen-binding protein maintains. Sperm production stops even though blood testosterone is high. Recovery after cessation takes months to years, and is sometimes incomplete.
- Gynecomastia, because excess androgen is aromatized to estradiol in adipose tissue.
- Polycythemia, because androgens stimulate erythropoietin — raising hematocrit and with it thrombotic risk.
- Adverse lipids and cardiac remodeling: HDL falls sharply, LDL rises, and left ventricular hypertrophy with impaired relaxation is well documented in long-term users.
The male athlete triad is the less publicized mirror of the female one. In men, sustained low energy availability — endurance athletes, weight-class sports, aesthetic sports — suppresses the GnRH pulse generator just as it does in women. The result is low energy availability → hypogonadotropic hypogonadism (low LH, low testosterone) → reduced bone mineral density, with stress fractures as the presenting problem. Because men have no menstrual cycle to lose, there is no obvious warning sign, so the condition is recognized late. The relative energy deficiency in sport (RED-S) framework was extended to cover exactly this gap, and low testosterone in a lean male endurance athlete should prompt questions about energy intake before it prompts a prescription.
Check Your Understanding 27.3
- A man has normal testosterone, normal LH, azoospermia, and an FSH of 22 mIU/mL. Where is the problem, and how do you know?
- Explain why a man taking high-dose testosterone for bodybuilding becomes infertile, using the axis and the blood-testis barrier.
- Why does a cross-section of a seminiferous tubule contain many primary spermatocytes but almost no secondary spermatocytes?
Show answers
- The problem is in the seminiferous tubules / Sertoli cell compartment — a primary testicular failure of the gamete-producing arm, with the hormone-producing arm intact. The reasoning uses the two-signal feedback structure: testosterone is normal and LH is normal, so the Leydig-cell-LH loop is working. FSH is high, which means its selective inhibitor, inhibin B, is low, which means the Sertoli cells are damaged or the germ cell population they support is absent. This is the classic pattern of non-obstructive azoospermia, and it distinguishes it from obstructive azoospermia, where FSH and inhibin B are normal because the tubules are working and the blockage is downstream.
- Exogenous testosterone raises blood levels, which suppresses GnRH and therefore LH and FSH. Without LH, the Leydig cells stop producing testosterone inside the testis; without FSH, Sertoli cells make less androgen-binding protein. Since spermatogenesis requires an intratubular testosterone concentration roughly 100 times that of plasma — maintained by local production plus ABP behind the blood-testis barrier — even a very high blood level cannot substitute, because the barrier that protects germ cells also isolates them from the circulation. High testosterone everywhere except the one place it is needed.
- Because the stages have wildly different durations. Prophase of meiosis I lasts about 22 days, so at any instant a large fraction of germ cells are primary spermatocytes. Secondary spermatocytes exist for only about 8 hours before completing meiosis II. A histological section is a random sample in time, so it is dominated by whatever stage lasts longest. The same reasoning explains why anaphase figures are rare in any mitotically active tissue.
27.4 Female Anatomy
Ovaries and their ligaments
Each ovary is almond-shaped, about 3 × 1.5 × 1 cm, held in the pelvis by three structures: the ovarian ligament (ovary to uterus), the suspensory ligament of the ovary (ovary to pelvic wall, carrying the ovarian artery and vein), and the mesovarium, a fold of the broad ligament.
One anatomical fact governs a surprising amount of gynecology: the ovary is not continuous with the uterine tube. The oocyte is released into the peritoneal cavity and must be captured. It usually is, by fimbriae sweeping across the ovarian surface — but the gap is real, and it is the reason that ectopic pregnancy can occur outside the tube altogether, that endometrial tissue can reach the peritoneum (§27.10), and that ovarian cancer disseminates transperitoneally and presents late. The female reproductive tract is the only place in the body where the peritoneal cavity communicates with the outside world.
The uterine tubes
Each tube is about 10 cm long, with four regions from lateral to medial: the infundibulum with its finger-like fimbriae (one of which, the ovarian fimbria, attaches to the ovary); the ampulla, the widest segment and the normal site of fertilization; the narrow isthmus; and the intramural part passing through the uterine wall.
Transport is not passive. Three mechanisms cooperate: fimbriae sweep across the ovary at ovulation; ciliated epithelium beats toward the uterus; and smooth muscle peristalsis moves the oocyte along. The journey takes three to four days, and the delay is functional — it gives the embryo time to reach the blastocyst stage and the endometrium time to become receptive.
Damage the cilia and the muscle, as chlamydial or gonococcal pelvic inflammatory disease does, and two things follow: the oocyte or embryo may never arrive, giving tubal factor infertility, or it may arrive too slowly and implant in the tube, giving ectopic pregnancy. One infection, two opposite-looking outcomes, both explained by transport failure.
The uterus, and the vascular basis of menstruation
The uterus is a thick-walled muscular organ about 7.5 × 5 × 2.5 cm, comprising the fundus, body, isthmus, and cervix. It is normally anteverted (tipped forward on the vagina) and anteflexed (bent forward on itself), resting on the bladder. Its principal supports are the cardinal (transverse cervical) ligaments and the pelvic floor muscles; the broad ligament is a peritoneal fold that suspends rather than supports, and the round ligaments, homologues of the gubernaculum, help maintain anteversion.
Three layers:
| Layer | Tissue | Notes |
|---|---|---|
| Perimetrium | Visceral peritoneum | The outer serosa |
| Myometrium | Three interwoven layers of smooth muscle | The bulk of the wall; hypertrophies enormously in pregnancy; contracts under oxytocin and prostaglandins |
| Endometrium | Simple columnar epithelium plus a glandular lamina propria | Divided into two functionally distinct strata |
The endometrium's two strata are the key to the whole cycle:
- Stratum functionalis — the superficial two-thirds. Built up and shed every month.
- Stratum basalis — the deep third, adjacent to the myometrium. Permanent. It regenerates the functionalis after each menstruation.
And the blood supply is arranged to match, which is where menstruation actually comes from.
FEMALE REPRODUCTIVE TRACT — anterior view (left) and sagittal (right)
═══ ANTERIOR VIEW ══════════════ ═══ SAGITTAL (MIDLINE) VIEW ══════
sacrum ╲
fundus ╲
╭──────────────╮ ┌───┐ uterus ╲
╱ UTERUS ╲ │ │ (ANTEVERTED ╲
│ ┌──────────┐ │ ← uterine tube ╱ ╲ │ and ANTE- │
│ │endometrium│ │ (ampulla = site │ ╲ │ FLEXED) │
│ │myometrium │ │ of fertilization)│ ▓▓ ╲│ │
│ │perimetrium│ │ │ ▓▓ ╲ ← recto- │
│ └──────────┘ │ ╲ ▓▓ ╲ uterine │
├──fimbriae ○○○───┤ ╲___ ╲ pouch │
│ ╱ ╲ │ ← OVARY is NOT BLADDER ╲ (of Douglas)
│ ○ OVARY ○ │ continuous with ___ ╲ │
│ ╲ ╱ │ the tube: the ╱ pubis╲ ╲ cervix │
├─────────────────┤ oocyte crosses │ ╲ ╲ │ │
│ isthmus │ the PERITONEAL │ urethra ╲ ╲ ▼ │
├─────────────────┤ CAVITY │ │ ╲ VAGINA │
│ CERVIX │ ╰────┴──────╲───┬────╯
│ external os ○ │ ╲ │
╰────────┬────────╯ ╲ ▼ RECTUM
╭───┴────╮ vestibule ── ○ ○
│ VAGINA │ pH 3.5–4.5
╰────────╯ (lactobacilli → lactic acid)
═══ THE BLOOD SUPPLY THAT EXPLAINS MENSTRUATION ═══════════════════
uterine artery
│
ARCUATE arteries (encircle the uterus within the myometrium)
│
RADIAL arteries (penetrate inward)
│
├──────────────► STRAIGHT arteries ──► STRATUM BASALIS
│ NOT hormone-sensitive (deep 1/3)
│ SURVIVE menstruation PERMANENT
│ regenerates the
│ functionalis
│
└──────────────► SPIRAL arteries ────► STRATUM FUNCTIONALIS
coiled; HIGHLY (superficial 2/3)
sensitive to SHED each month
PROGESTERONE
MENSTRUATION, MECHANICALLY:
corpus luteum dies → PROGESTERONE FALLS
→ spiral arteries undergo spasmodic CONSTRICTION
→ stratum functionalis becomes ISCHEMIC and NECROSES
→ arteries then relax; damaged vessels RUPTURE
→ blood sloughs the dead functionalis
Straight arteries never constricted → basalis survives → rebuild
Figure 27.4 — The female reproductive tract in anterior and sagittal view, and the uterine blood supply that makes menstruation mechanical.
Described: Two views of the female reproductive tract plus a diagram of the uterine blood supply. The anterior view shows the uterus with its fundus at the top and its three layers — endometrium innermost, myometrium in the middle, perimetrium outermost — with a uterine tube extending laterally on each side to fimbriae, and an ovary beneath each set of fimbriae; the diagram notes that the ovary is not continuous with the tube, so the oocyte crosses the peritoneal cavity, and that the ampulla of the tube is the normal site of fertilization. Below the body of the uterus are the isthmus, the cervix with its external os, and the vagina, whose pH is 3.5 to 4.5 because lactobacilli produce lactic acid. The sagittal midline view shows the uterus lying anteverted and anteflexed over the bladder, with the pubis and urethra anteriorly, the vagina descending behind the urethra, the cervix projecting into the vaginal vault, the rectouterine pouch of Douglas behind the uterus, and the rectum and sacrum posteriorly. The blood supply diagram traces the uterine artery into arcuate arteries encircling the uterus within the myometrium, then radial arteries penetrating inward, which divide into two functionally different sets. Straight arteries supply the stratum basalis, the deep one-third of the endometrium; they are not hormone-sensitive and survive menstruation, so the basalis is permanent and regenerates the functionalis. Spiral arteries supply the stratum functionalis, the superficial two-thirds; they are coiled and highly sensitive to progesterone. Menstruation is then explained mechanically: when the corpus luteum dies and progesterone falls, the spiral arteries constrict spasmodically, the stratum functionalis becomes ischemic and necroses, the arteries then relax and the damaged vessels rupture, and blood sloughs the dead functionalis — while the straight arteries, which never constricted, keep the basalis alive to rebuild it.
That figure contains the answer to a question students rarely think to ask: why does the uterus bleed rather than simply reabsorbing the lining? Because the tissue is killed by deliberate ischemia before it is shed, and killing it requires shutting off its blood supply, and turning the supply back on through damaged vessels means bleeding. Menstruation is the debris of a controlled infarction — and the reason it is self-limiting is that the basalis, on a separate and hormone-insensitive circulation, was never at risk.
Vagina, external genitalia, and perineum
The vagina is an 8–10 cm fibromuscular tube lined by non-keratinized stratified squamous epithelium — the epithelium of abrasion resistance (Chapter 4). It contains no glands; lubrication comes from transudate across the wall, cervical mucus, and the greater vestibular glands. Under estrogen the epithelium accumulates glycogen, which resident lactobacilli ferment to lactic acid, holding vaginal pH at 3.5–4.5. That acidity is a genuine antimicrobial barrier, and losing it — after menopause, when estrogen and therefore glycogen fall — is one of the reasons urinary and vaginal infections become more common with age (see the UTI sidebar in Chapter 26, §26.9).
The vulva comprises the mons pubis, labia majora (homologues of the scrotum), labia minora (homologues of the ventral penile shaft), the clitoris — which, like the penis, has erectile crura and vestibular bulbs extending well beyond the visible glans — the vestibule, the external urethral orifice, the vaginal orifice, and the greater (Bartholin) and lesser (Skene) vestibular glands.
The perineum is the diamond bounded by the pubic symphysis, the ischial tuberosities, and the coccyx, divided by a line between the tuberosities into a urogenital triangle and an anal triangle. The perineal body, the fibromuscular node at their junction, is the anchor for the pelvic floor muscles and the structure most at risk during childbirth — its disruption is a major contributor to later pelvic organ prolapse and stress incontinence (§26.9).
The mammary glands
The breasts are modified apocrine sweat glands — the derivation is not trivia, it explains their structure. Each contains 15–25 lobes radiating from the nipple, each lobe subdivided into lobules of alveoli, draining through lactiferous ducts to lactiferous sinuses beneath the areola. Suspensory (Cooper's) ligaments tether the gland to the dermis; their infiltration by tumour is what produces skin dimpling.
At puberty, estrogen drives duct growth and fat deposition while progesterone promotes alveolar development; the gland is not functional until pregnancy, when prolactin and oxytocin complete the job (Chapter 28). Roughly 75% of lymphatic drainage goes to the axillary nodes, which is why axillary examination and sentinel node biopsy are central to breast cancer staging.
Imaging · Seeing Follicles, Tubes, and Prostates
Transvaginal ultrasound places a high-frequency probe within a few centimetres of the ovaries and uterus, so it achieves resolution that abdominal scanning cannot. Three routine uses:
- Antral follicle count. Small antral follicles of 2–9 mm are counted in both ovaries in the early follicular phase. The total is a direct anatomical measure of ovarian reserve and correlates with AMH. A count above about 15 suggests a large reserve (and is one of the Rotterdam criteria for polycystic ovarian morphology); a count below 5–7 suggests diminished reserve. In Amara, with an AMH of 0.3 ng/mL, this count would be very low.
- Follicle tracking. During ovulation induction or IVF, serial scans measure the dominant follicle's diameter as it grows about 2 mm per day toward 18–24 mm, at which point the trigger injection is given. You are watching Figure 27.5 happen in real time.
- Endometrial thickness. The endometrium is measured as a double layer and its appearance changes with phase — a thin bright line just after menstruation, a trilaminar three-line appearance in the late proliferative phase, and a thick uniformly bright appearance in the secretory phase. In a post-menopausal woman, a thickness above 4–5 mm with bleeding requires investigation for endometrial cancer.
Hysterosalpingography (HSG) injects radio-opaque contrast through the cervix under fluoroscopy. It outlines the uterine cavity and, if the tubes are patent, spills contrast into the peritoneal cavity — visible as free contrast pooling around the bowel. It answers two questions in one study: is the cavity normal (septum, fibroid, adhesions) and are the tubes open. It has a curious and well-documented side effect: pregnancy rates rise modestly in the months after the procedure, probably because the oil-based contrast flushes debris and alters the peritoneal environment.
Prostate imaging has two roles. Transrectal ultrasound measures prostate volume, which guides treatment choice in benign prostatic hyperplasia, and guides biopsy needles. Multiparametric MRI has largely taken over the diagnostic role for cancer, because it distinguishes the peripheral zone — where about 70% of cancers arise, and which is what a finger reaches on digital rectal examination — from the transition zone around the urethra, which is where benign hyperplasia grows. That zonal difference is why a man can have a large obstructing prostate and no cancer, or a normal-sized prostate and a significant tumour.
Check Your Understanding 27.4
- Why does the stratum basalis survive menstruation while the stratum functionalis does not?
- A woman has severe pelvic pain and a positive pregnancy test, with an empty uterus on ultrasound. Using anatomy alone, name the two most likely locations of the pregnancy and explain why the female tract permits this at all.
- Why is the vagina's acidity dependent on estrogen, and what happens to it after menopause?
Show answers
- Because they are on separate arterial supplies with different hormonal sensitivities. The functionalis is fed by spiral arteries, which are exquisitely sensitive to progesterone withdrawal and undergo spasmodic constriction when the corpus luteum dies — producing the ischemic necrosis that is shed. The basalis is fed by straight arteries, which are not hormone-responsive, do not constrict, and keep the basalis alive. A permanent layer with a protected blood supply is the only way to have a tissue that can be destroyed and rebuilt monthly for four decades.
- Most likely the ampulla of the uterine tube (the commonest ectopic site, because it is where fertilization normally occurs and where slowed transport strands the embryo), and second the peritoneal cavity or ovarian surface (abdominal or ovarian ectopic). This is possible because the ovary is not continuous with the tube: the oocyte is released into the peritoneal cavity, so the female tract is open to the abdomen. It is the only such communication in the body, and it is why an ectopic pregnancy is a surgical emergency — the tube has no capacity to expand and ruptures into a cavity with a rich blood supply.
- Estrogen causes the vaginal epithelium to thicken and to accumulate glycogen. Resident lactobacilli ferment that glycogen to lactic acid, holding the pH at 3.5–4.5. After menopause, estrogen falls, the epithelium thins and stores less glycogen, lactobacilli decline, and pH rises toward 6. The consequences are a shift in the vaginal microbiome toward uropathogens (raising the rate of recurrent urinary tract infection), plus dryness, fragility, and dyspareunia — the syndrome called genitourinary syndrome of menopause, and the reason topical vaginal estrogen is effective for it.
27.5 Oogenesis and the Ovarian Cycle
A pool that only shrinks
Spermatogenesis is a factory: stem cells divide continuously and production is limited only by resources. Oogenesis is an inventory, established once and drawn down for the rest of life.
| Stage | Number of oocytes |
|---|---|
| Peak, at ~20 weeks of gestation | 6–7 million |
| At birth | 1–2 million |
| At puberty | 300,000–400,000 |
| Ovulated across a lifetime | ~400–500 |
| At menopause | fewer than 1,000 |
Two facts control everything downstream. Mitosis stops before birth — the oogonia have finished dividing by about the fifth month of fetal life, so no new oocytes are ever made. And the losses are enormous: about 99.9% of the peak pool disappears by atresia, a programmed apoptotic attrition that runs continuously from mid-gestation to menopause and is largely independent of gonadotropins, of pregnancy, and of contraception. Ovulating fewer times does not preserve the pool.
That relentless, gonadotropin-independent attrition is the reason menopause happens at a fairly predictable age, and it is the reason §27.8's answer to Amara's FSH is what it is.
Two arrests, and why they matter
Oogenesis contains two long pauses that have no equivalent in the male.
Arrest 1 — prophase I, from fetal life until ovulation. Every oocyte enters meiosis I before birth and stops in prophase I (the dictyate stage). It stays there for 12 to 50 years. An oocyte ovulated by a 45-year-old has been holding its chromosomes paired, with its spindle apparatus and cohesin proteins in place, since before that woman was born.
This is the mechanistic basis of maternal age-related aneuploidy. Cohesin — the protein complex that holds sister chromatids together — is loaded before birth and is not replenished. Over decades it degrades, so chromosomes are more likely to segregate incorrectly when meiosis I finally completes. The clinical numbers follow the biology: the risk of a trisomy 21 pregnancy rises from roughly 1 in 1,500 at maternal age 20 to about 1 in 85 at 40 and 1 in 35 at 45. Note that paternal age has a different signature — an increased rate of new point mutations rather than aneuploidy — because sperm are made continuously from dividing stem cells, so the errors that accumulate are copying errors rather than segregation errors.
Arrest 2 — metaphase II, until fertilization. The LH surge triggers completion of meiosis I, producing a secondary oocyte and the first polar body. The secondary oocyte immediately enters meiosis II and arrests again at metaphase II. It is ovulated in that state. Meiosis II completes only if a sperm penetrates — which is why the cell that is ovulated is technically a secondary oocyte, and a true ovum exists only for the few minutes between sperm entry and the fusion of the two pronuclei.
Cytokinesis is deliberately unequal. Each division gives essentially all the cytoplasm to one daughter and almost none to the other, which is discarded as a polar body. The point is economy of provisioning: one primary oocyte yields one enormous, fully stocked gamete rather than four inadequate ones. Compare the arithmetic — one primary spermatocyte yields four sperm; one primary oocyte yields one ovum and two or three polar bodies.
Follicular development
ONE FOLLICLE'S JOURNEY AROUND THE OVARY
(the full trip takes ~1 year; only the last ~14 days are FSH-driven)
╭─────────────────────────────────╮
│ THE OVARY │
PRIMORDIAL │ │
FOLLICLE ────┼──► PRIMARY ──► SECONDARY ───┐ │
oocyte + │ cuboidal multilayered │ │
1 flat layer │ granulosa granulosa + │ │
(the resting │ + ZONA THECA │ │
pool) │ PELLUCIDA INTERNA and │ │
▲ │ appears EXTERNA ▼ │
│ │ ANTRAL │
most undergo │ (tertiary,│
ATRESIA │ vesicular)│
(~99.9%) │ antrum │
│ │ forms; │
│ │ cumulus │
│ │ oophorus │
│ │ │ │
│ │ ▼ │
│ │ PREOVULATORY │
│ │ (GRAAFIAN) │
│ │ 18–24 mm; │
│ │ bulges from │
│ │ the surface │
│ │ │ │
│ │ ★ LH SURGE ─────┤ │
│ │ ▼ │
│ │ OVULATION │
│ │ oocyte + corona │
│ │ radiata released │
│ │ into the PERITONEAL │
│ │ CAVITY ──────────────┼──► fimbriae
│ │ │ │
│ │ ▼ │
│ │ CORPUS LUTEUM │
│ │ granulosa + theca│
│ │ LUTEINIZE; │
│ │ PROGESTERONE + │
│ │ estradiol + │
│ │ inhibin A │
│ │ lifespan 14 ± 2 d│
│ │ unless rescued │
│ │ by hCG │
│ │ │ │
│ │ ▼ │
└───────┤ CORPUS ALBICANS │
│ a white scar │
╰─────────────────────────────────╯
THE TWO-CELL, TWO-GONADOTROPIN MODEL — neither cell can do it alone
┌──────────────────────────┐ ┌───────────────────────────┐
│ THECA INTERNA CELL │ │ GRANULOSA CELL │
│ receptor: LH │ │ receptor: FSH │
│ cholesterol → ANDRO- │───────►│ ANDROSTENEDIONE │
│ STENEDIONE │diffuses│ │ AROMATASE │
│ (NO aromatase — cannot │ across│ ▼ │
│ finish the job) │ the BM│ ESTRADIOL │
│ │ │ + INHIBIN B │
└──────────────────────────┘ └───────────────────────────┘
Figure 27.5 — The ovarian cycle as one follicle's journey, with the two-cell model of steroid synthesis.
Described: A circular diagram tracing one follicle around the ovary. It begins as a primordial follicle — an oocyte surrounded by a single flat layer of follicle cells, the resting pool — and becomes a primary follicle with cuboidal granulosa cells and a newly appearing zona pellucida, then a secondary follicle with multiple granulosa layers and a theca that differentiates into theca interna and theca externa, then an antral or tertiary or vesicular follicle in which a fluid-filled antrum forms and the cumulus oophorus surrounds the oocyte, and finally a preovulatory or Graafian follicle of 18 to 24 millimetres that bulges from the ovarian surface. A side arrow notes that about 99.9 percent of follicles instead undergo atresia at every stage. The LH surge triggers ovulation, in which the oocyte and its corona radiata are released into the peritoneal cavity and swept up by the fimbriae. The remaining granulosa and theca cells luteinize to form the corpus luteum, which secretes progesterone, estradiol, and inhibin A and lives 14 plus or minus 2 days unless rescued by human chorionic gonadotropin; otherwise it regresses to a white scar called the corpus albicans. A note states that the full journey from primordial follicle to ovulation takes about a year and that only the last fourteen days or so are driven by FSH. Below, the two-cell, two-gonadotropin model is drawn as two boxes: the theca interna cell carries LH receptors and converts cholesterol to androstenedione but lacks aromatase and cannot finish the job, while the granulosa cell carries FSH receptors, receives the androstenedione that diffuses across the basement membrane, and uses aromatase to convert it to estradiol, also secreting inhibin B. Neither cell can make estrogen alone.
Two details in that figure do a lot of work later.
The journey is a year long, and only the last fortnight is under pituitary control. Recruitment from the primordial pool, and growth through the primary and secondary stages, proceed independently of FSH and LH. Only at the antral stage does a follicle become gonadotropin-dependent. This is why hormonal contraception does not preserve the ovarian reserve, and why anti-Müllerian hormone — secreted by small growing follicles at the gonadotropin-independent stage — is the best available measure of how many follicles remain. Amara's AMH of 0.3 ng/mL is a direct count of what is left.
The two-cell model means estrogen requires both gonadotropins. LH drives theca cells to make androstenedione; theca cells have no aromatase and cannot go further. The androgen diffuses across the basement membrane into granulosa cells, where FSH-induced aromatase converts it to estradiol. Remember this when you meet polycystic ovary syndrome in §27.10, where an altered LH:FSH ratio drives the theca side hard while the granulosa side lags, and androgens accumulate.
Histology · Staging a Follicle Down the Microscope
An ovarian cortex section contains follicles at every stage simultaneously, and staging them is a standard practical examination question. Work outside-in and count layers.
| Stage | What you see |
|---|---|
| Primordial | Small oocyte surrounded by a single layer of flat (squamous) follicle cells. Crowded in the outermost cortex. The most numerous by far. |
| Primary, unilaminar | The same, but the follicle cells are now cuboidal. |
| Primary, multilaminar | Several layers of granulosa cells, and a zona pellucida appears as a bright pink glassy band immediately around the oocyte. |
| Secondary (preantral) | Many granulosa layers; the surrounding stroma organizes into theca interna (rounded, pale, steroid-secreting cells) and theca externa (spindle-shaped fibrous cells). |
| Antral / vesicular | One or more fluid-filled antra coalescing into a single crescent. The oocyte sits in a mound of granulosa cells, the cumulus oophorus; the innermost ring adhering to the zona is the corona radiata. |
| Corpus luteum | No oocyte. A large, folded, intensely eosinophilic body of two cell types: large pale granulosa lutein cells centrally and smaller, darker theca lutein cells at the periphery. Vascularized throughout. |
| Corpus albicans | Acellular, pale, wavy collagen scar. Shrinks over months. |
| Atretic follicle | A collapsed follicle with a wrinkled, often free-floating zona pellucida and pyknotic granulosa nuclei. Common at every stage — remember that atresia is the normal fate. |
Two identifying tips. The zona pellucida is the single most useful landmark: it is a distinctly refractile glassy band, and its persistence in a collapsed follicle is the giveaway for atresia. And the theca interna's pale, vacuolated cytoplasm is the classic appearance of a steroid-secreting cell — abundant smooth endoplasmic reticulum and lipid droplets, exactly as in the adrenal cortex and the Leydig cell. Steroid producers look alike everywhere in the body, which is a structure-function point you can use as a diagnostic shortcut.
Check Your Understanding 27.5
- Why does the risk of chromosomal aneuploidy rise with maternal age but not, in the same way, with paternal age?
- A patient asks whether taking the contraceptive pill for ten years will "save up" her eggs and delay menopause. Answer her, with the mechanism.
- Why is AMH a better measure of ovarian reserve than FSH?
Show answers
- Because of the two different reproductive strategies. Oocytes are all made before birth and arrest in prophase I for 12–50 years, holding their chromatids together with cohesin proteins that were loaded in fetal life and are not replenished. Cohesin degrades with time, so the older the oocyte, the more likely that chromosomes mis-segregate when meiosis I finally completes — producing aneuploidy, most commonly trisomy. Sperm, by contrast, are produced continuously from stem cells that keep dividing, so the errors that accumulate with paternal age are replication errors — new single-nucleotide mutations, whose rate rises roughly linearly with paternal age — not segregation errors.
- No. The pool is drawn down overwhelmingly by atresia, which runs continuously from mid-gestation onward and is largely independent of gonadotropins. Only the final antral stage of follicle growth is FSH-dependent, and the pill suppresses only that final stage. Of the roughly 1,000 follicles lost per month in a young adult, one is ovulated and the rest die anyway, so preventing that one ovulation preserves about 0.1% of the monthly loss. Combined hormonal contraception has many benefits, but delaying menopause is not among them, and studies of age at menopause in long-term users bear that out.
- Because AMH and FSH measure different things at different removes. AMH is secreted directly by the granulosa cells of small growing (preantral and early antral) follicles, at a stage that is gonadotropin-independent, so it is close to a direct headcount of the remaining pool and is stable across the cycle. FSH is a pituitary response to feedback signals — inhibin B and estradiol — from whichever follicles happen to be growing this month, so it is one step removed and fluctuates dramatically from cycle to cycle in perimenopause. A normal FSH on one day does not exclude diminished reserve; a low AMH is far harder to explain away.
27.6 Hormonal Control of the Female Cycle
Everything in §27.5 happens because four hormones move in a fixed sequence over 28 days. Here is the sequence, and then the one feature that makes it unique in endocrinology.
Predict This
Throughout this book, rising estrogen has inhibited FSH and LH — standard negative feedback. Yet in the middle of the cycle, LH suddenly spikes about tenfold, at the exact moment estradiol is at its highest.
Before reading on: what must be true about estrogen's feedback for that to happen? Commit to an answer.
(Answer: the sign of the feedback must change. Above a threshold concentration, sustained for long enough, estradiol's effect on the hypothalamus and pituitary switches from negative to positive — the only such switch in the endocrine system apart from oxytocin in labor. The threshold is roughly 200 pg/mL sustained for 36–48 hours, and it is a threshold in both amount and duration, which is what prevents accidental surges.)
The 28 days, hormone by hormone
Days 1–5 · Early follicular. The corpus luteum of the previous cycle has died, so estradiol, progesterone, and inhibin A have all collapsed. Released from their inhibition, FSH rises. It recruits a cohort of antral follicles — perhaps 5 to 20 of them — that had reached the gonadotropin-dependent stage.
Days 5–7 · Selection. The follicles compete. The one with the most FSH receptors and the best blood supply grows fastest and makes the most estradiol and inhibin B. Both of those suppress FSH. Because the dominant follicle has by now acquired enough receptors to keep growing on a falling FSH level — and its rivals have not — the winner starves the competition by consuming the resource everyone depends on. The others undergo atresia. This is why a single follicle usually ovulates, and why giving exogenous FSH (as in IVF) overrides the selection and produces multiple follicles.
Days 7–12 · Late follicular. The dominant follicle becomes progressively FSH-independent, acquiring LH receptors on its granulosa cells. Estradiol rises steeply — from about 40 pg/mL to over 250 pg/mL. Meanwhile the endometrium proliferates (§27.7) and cervical mucus thins.
Days 12–14 · The switch and the surge. Once estradiol has exceeded roughly 200 pg/mL for 36–48 hours, two things change at once: hypothalamic GnRH pulse frequency increases, and the pituitary gonadotropes become dramatically more sensitive to GnRH. The result is an abrupt, roughly tenfold LH surge, with a smaller FSH rise alongside it.
Ovulation follows about 36 hours after the surge begins and about 10–12 hours after its peak. (Home ovulation predictor kits detect the surge in urine, which is why they predict ovulation about a day and a half ahead.) The surge does three things: it triggers completion of meiosis I; it induces proteolytic enzymes, prostaglandins, and matrix metalloproteinases that digest the follicle wall at a weak point called the stigma; and it begins luteinization of the granulosa and theca cells.
Days 15–26 · Luteal. The corpus luteum secretes progesterone (its dominant product, peaking around 10–20 ng/mL at day 21), plus estradiol and inhibin A. Together these exert powerful negative feedback: progesterone slows GnRH pulse frequency, and the combination suppresses FSH and LH so that no new follicle is recruited. This is precisely the state that combined hormonal contraception imitates.
Days 26–28 · Luteolysis. In the absence of hCG from an implanting embryo, the corpus luteum has a fixed lifespan of 14 ± 2 days and regresses. Progesterone, estradiol, and inhibin A all fall. Two consequences: menstruation begins (§27.7), and FSH — disinhibited — rises to start the next cycle. The luteal phase's fixed length is why variation in cycle length comes almost entirely from the follicular phase: a 35-day cycle has a 21-day follicular phase, not a longer luteal one.
THE FEMALE CYCLE ON ONE 28-DAY AXIS (day 1 = first day of bleeding)
A · GONADOTROPINS
LH ─────────────────────────────╱╲──────────────────────────
╱ ╲ ★ LH SURGE (~10×)
..............................╱ ╲.....................
FSH ──╲___ ╱‾╲ ╲___ ___╱
‾‾‾‾╲___________╱‾‾ ‾╲ ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾
▲ FSH rises when ▲ FSH rises again
inhibin+estradiol fall (luteolysis)
B · OVARIAN HORMONES
ESTRADIOL ______________________╱╲______╱‾‾‾‾‾╲___________
╱‾‾‾‾‾‾‾‾‾╱ ╲ ╱ ╲
____╱‾‾‾‾‾ ╲__╱ ╲______
PROGESTERONE _________________________╱‾‾‾‾‾‾‾‾╲__________
................................___╱ ╲.......
▲ corpus luteum ▲ luteolysis
C · FOLLICLE / OVARIAN CYCLE
○ ○ ○ ○ ◎ ◍ ● ☀ ✿ ·
recruited selected dominant Graafian OVULATION corpus corpus
cohort follicle 18–24 mm day 14 luteum albicans
|──────── FOLLICULAR PHASE (VARIABLE) ────| |LUTEAL 14±2|
D · ENDOMETRIUM (uterine cycle) — thickness in mm
14 ┤ ░░░░░░░░░░
12 ┤ ▒▒▒▒▒▒▒▒▒▒░░░░░░░░░░
10 ┤ ▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒░░░░░░░░░░
8 ┤ ▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒░░░░░░░░░░
6 ┤ ▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒░░░░░░░░░░
4 ┤▓▓▓▓▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒░░░░░░░░░▓▓
2 ┤▓▓▓▓ ▓▓
0 └─┬────┬────┬────┬────┬────┬────┬────┬────┬────┬────┬──
1 4 7 10 13 14 17 20 23 26 28
▓ MENSTRUAL ▒ PROLIFERATIVE ░ SECRETORY
(1–5) (6–14, estrogen) (15–28, progesterone)
E · BASAL BODY TEMPERATURE
36.9 ┤ ┌──────────────────┐
36.7 ┤ │ LUTEAL PLATEAU │
36.5 ┤──────────────────────────────┘ +0.3 to 0.5 °C └──
36.3 ┤ FOLLICULAR BASELINE (progesterone raises
└──────────────────────────────────the hypothalamic
SET POINT)
Figure 27.6 — Gonadotropins, ovarian hormones, follicle development, endometrial thickness, and basal body temperature on a shared 28-day axis.
Described: Five stacked panels sharing a horizontal axis of 28 days, with day one defined as the first day of bleeding. Panel A shows the gonadotropins: FSH is high in the first days, falls through the mid-follicular phase as estradiol and inhibin B rise, shows a small mid-cycle rise, is suppressed through the luteal phase, and rises again at the end of the cycle as the corpus luteum regresses; LH is low and flat until a sharp roughly tenfold surge just before day 14, then returns to a low level. Panel B shows the ovarian hormones: estradiol rises progressively through the follicular phase to a peak just before the LH surge, dips briefly at ovulation, then rises to a lower second peak in the mid-luteal phase before falling; progesterone is negligible throughout the follicular phase, rises sharply after ovulation to a mid-luteal peak, and collapses at luteolysis. Panel C shows the follicle: a recruited cohort of antral follicles in the first days, selection of a dominant follicle by about day seven, growth to a Graafian follicle of 18 to 24 millimetres, ovulation on about day 14, then the corpus luteum through the luteal phase and finally the corpus albicans. It marks the follicular phase as variable in length and the luteal phase as fixed at 14 plus or minus 2 days. Panel D plots endometrial thickness in millimetres: about 2 to 4 millimetres during the menstrual phase on days one to five, rising steadily through the proliferative phase under estrogen to about 10 millimetres by day 14, continuing to about 12 to 14 millimetres through the secretory phase under progesterone, then dropping abruptly at the end of the cycle. Panel E plots basal body temperature: a follicular baseline near 36.4 degrees Celsius, then a step up of 0.3 to 0.5 degrees to a luteal plateau near 36.8 degrees beginning just after ovulation and sustained until menstruation, caused by progesterone raising the hypothalamic thermoregulatory set point.
Thread 2 · Homeostasis Is the Master Concept — and the One Place It Reverses
Chapter 1 made a claim: more than 99% of the body's control loops are negative feedback, because negative feedback produces stability, and positive feedback produces escalation. It listed three normal positive feedback loops: clotting, labor, and the action potential.
The LH surge is the fourth, and it is the only one in which a hormone's feedback sign changes rather than a different mechanism being used. Below about 200 pg/mL, estradiol inhibits GnRH and LH. Above that threshold, sustained for 36–48 hours, the same hormone acting on the same tissues stimulates them. Estradiol drives GnRH, GnRH drives LH, LH drives more estradiol, and the system escalates for about a day and a half.
And, exactly as Chapter 1 predicted of every safe positive loop, it has a built-in endpoint: ovulation destroys the follicle that was making the estradiol, and the luteinized remnant switches to producing progesterone, which restores negative feedback and slams the loop shut. The escalation terminates by consuming its own stimulus, precisely as the fetal head leaving the cervix terminates the oxytocin loop of labor.
Why use positive feedback at all? For the same reason as clotting and labor: because ovulation must be fast, complete, and irreversible. A slow, graded LH rise would produce a follicle that partly ruptured, which is worse than either outcome. When physiology needs a switch rather than a dial, it reaches for positive feedback — and then engineers a brake.
Check Your Understanding 27.6
- A woman's cycles run 35 days. On approximately which day did she ovulate, and how do you know?
- Explain how the combined oral contraceptive pill prevents ovulation, naming three separate mechanisms.
- Why does an FSH-only stimulation protocol in IVF produce many mature follicles instead of one?
Show answers
- About day 21. The luteal phase is fixed at 14 ± 2 days because the corpus luteum has an intrinsic lifespan and dies on schedule unless rescued by hCG. Cycle length therefore varies almost entirely in the follicular phase. Working backwards from a 35-day cycle: 35 − 14 = 21. This is why "day 14" is a convention for a 28-day cycle rather than a biological constant, and why counting forward from the last period is an unreliable way to time intercourse or a progesterone test — a mid-luteal progesterone should be drawn seven days before the expected period, not on day 21 regardless.
- Three mechanisms, in descending order of importance: (i) suppression of FSH, so no antral follicle cohort is recruited and no dominant follicle develops; (ii) suppression of the LH surge, because the steady exogenous estrogen never crosses the threshold-plus-duration requirement for the feedback switch, and the progestin holds GnRH pulse frequency low; (iii) progestin effects downstream — thickened, scanty cervical mucus that sperm cannot penetrate, and a thinned, unreceptive endometrium. The third set is why progestin-only methods work even when they do not reliably suppress ovulation.
- Because exogenous FSH removes the competition that normally selects a single follicle. In a natural cycle, the dominant follicle's estradiol and inhibin B suppress FSH, and the rest of the cohort — which still needs FSH — undergoes atresia. In a stimulation protocol, FSH is administered at a supraphysiological level and held there, so falling endogenous FSH no longer starves anyone. Every recruited follicle continues to grow, and ten or twenty may reach maturity. The same logic explains why ovulation induction agents raise the rate of twins: they interfere with a mechanism whose entire purpose is to guarantee that only one follicle wins.
27.7 The Uterine (Menstrual) Cycle
The ovarian cycle produces hormones; the uterine cycle is what those hormones do to the endometrium. The two run in lock-step, and the uterine phases are named for what the endometrium is doing.
| Phase | Days | Driving hormone | Endometrium | Cervical mucus |
|---|---|---|---|---|
| Menstrual | 1–5 | Withdrawal of progesterone | Functionalis shed; thickness falls to 0.5–2 mm (basalis only) | Scant |
| Proliferative | 6–14 | Estradiol from the growing follicle | Basalis regenerates functionalis; straight tubular glands; thickness to 8–10 mm; spiral arteries elongate | Thin, clear, alkaline, stretchy (spinnbarkeit), ferns on drying — sperm-friendly |
| Secretory | 15–28 | Progesterone from the corpus luteum | Glands become coiled and secrete glycogen-rich fluid; stroma becomes edematous; spiral arteries fully coiled; thickness 10–14 mm | Thick, scant, opaque — sperm-hostile |
Three points that are easy to miss.
Estrogen prepares the endometrium to hear progesterone. One of estradiol's proliferative-phase jobs is to induce progesterone receptors. Without the estrogen-driven priming, the secretory transformation cannot occur — which is a general principle of steroid physiology worth carrying forward: a hormone often has to install its successor's receptor.
Cervical mucus reverses twice a cycle, and the reversal is the point. Under estrogen it becomes thin, watery, and aligned into channels that sperm can swim through; under progesterone it becomes a thick plug. The window during which sperm can pass the cervix is therefore narrow and is estrogen-gated. Progestin-only contraception works largely by locking the mucus permanently into its hostile form.
The secretory endometrium is preparing for an embryo, not for a period. Glycogen secretion, stromal edema, and the beginnings of decidualization are provisioning for implantation. Menstruation is what happens when that preparation is not used, and it is best understood not as a cycle's purpose but as the cost of running the preparation speculatively every month.
Menstruation, mechanically
Return to Figure 27.4. When the corpus luteum dies, progesterone falls. Prostaglandin F2α is released, and the spiral arteries — which supply only the functionalis and are exquisitely progesterone-sensitive — undergo spasmodic constriction. The functionalis becomes ischemic and necroses over about a day. The arteries then relax; blood surges into vessels whose walls have been damaged by ischemia, and they rupture. The blood detaches and carries away the dead functionalis.
The straight arteries never constricted, so the basalis survives intact, with its stem cells, ready to rebuild. Normal blood loss is 30–80 mL over 4–5 days; above 80 mL is defined as heavy menstrual bleeding and is a common cause of iron deficiency anemia (Chapter 17).
Two clinical corollaries drop out. Prostaglandins cause the cramps — myometrial contraction and ischemia — which is why NSAIDs, which inhibit prostaglandin synthesis, are genuinely effective for dysmenorrhea rather than merely analgesic. And unopposed estrogen is dangerous: an endometrium exposed to estrogen without progesterone proliferates without ever undergoing the secretory transformation and the coordinated shed, which produces irregular breakthrough bleeding and, over years, endometrial hyperplasia and carcinoma. That is the mechanism behind the endometrial cancer risk of polycystic ovary syndrome, of obesity (adipose aromatase converts androgens to estrogen), and of estrogen-only hormone therapy in a woman who still has a uterus.
Case File question 2, answered: why the temperature moves
Nia's basal body temperature rises 0.4 °C — from 36.4 °C to 36.8 °C — within a day or two of ovulation and stays up until her period. That is squarely within the textbook range of 0.3–0.5 °C (0.5–1.0 °F), and the cause is progesterone.
Progesterone is thermogenic. It acts on the hypothalamic thermoregulatory centre — largely through its neurosteroid metabolite allopregnanolone acting on warm-sensitive preoptic neurons — and raises the set point. This is the exact logic of fever from Chapter 1: nothing is broken, no effector is failing. The thermostat has been moved, and the body then defends the new, higher target with entirely normal machinery. Progesterone also raises resting metabolic rate by roughly 2–8% (about 100–300 kcal/day), which contributes.
Two practical consequences follow. Because the rise happens after ovulation, basal body temperature identifies ovulation retrospectively, not prospectively — it confirms that ovulation occurred and is useless for predicting it in advance. And because the rise depends on progesterone, a sustained temperature elevation beyond 16–18 days is one of the earliest signs of pregnancy: hCG from the implanting embryo has rescued the corpus luteum, progesterone has not fallen, and the set point has not come back down.
And Nia's resting heart rate? It moves for related reasons. The higher core temperature itself raises heart rate (roughly 8–10 beats per minute per degree Celsius); progesterone raises metabolic rate; and progesterone is also a respiratory stimulant that increases ventilation and lowers arterial PCO₂ by 2–4 mm Hg in the luteal phase (Chapter 22), with modest cardiovascular consequences. Her +5 beats per minute is a normal, predictable, hormonally driven shift — and recognizing it as physiology rather than as overtraining is exactly why athletes who track resting heart rate need to know their cycle phase.
27.8 What Estrogen Does to the Rest of the Body
Estrogen and progesterone are usually taught as reproductive hormones. They are not. Estrogen receptors — the nuclear ERα and ERβ, plus the membrane receptor GPER for rapid, non-genomic effects — are expressed in bone, vascular endothelium, vascular smooth muscle, liver, adipose tissue, skin, and brain. Reproductive tissue is a minority of the target list.
Thread 3 · The Body Is Integrated
| System | What estrogen does | What losing it does |
|---|---|---|
| Bone (Chapter 6) | Restrains osteoclasts (raises osteoprotegerin, lowers RANKL); promotes osteoblast survival; closes the epiphyses in both sexes | Accelerated bone resorption: ~2% per year of trabecular bone for the first 5–8 post-menopausal years, then ~0.5–1%. This is Adwoa's osteoporosis, thirty years downstream |
| Vascular endothelium (Chapter 19) | Upregulates endothelial nitric oxide synthase and raises NO bioavailability; antioxidant; reduces adhesion molecule expression and smooth muscle proliferation | Reduced flow-mediated dilation; rising arterial stiffness (pulse wave velocity climbs measurably across the transition); rising blood pressure |
| Liver / lipids | Increases hepatic LDL receptor expression (clearing LDL); increases apoA-I (raising HDL); modestly raises triglycerides | LDL up, HDL down, small dense LDL particles increase, lipoprotein(a) rises |
| Adipose (Chapter 24) | Favours gluteofemoral subcutaneous fat storage | Redistribution to visceral fat, worsening insulin resistance and inflammatory adipokine output — waist rises even at stable weight |
| Brain | Stabilizes the hypothalamic thermoneutral zone via the KNDy (kisspeptin/neurokinin B/dynorphin) neurons; effects on mood, sleep architecture, and verbal memory | Hot flushes — a narrowed thermoneutral zone, so trivial temperature changes trigger full heat-dissipation responses; sleep disruption |
| Urogenital (Chapter 26) | Maintains vaginal glycogen and lactobacilli, urethral and trigonal epithelium, and periurethral collagen | Rising vaginal pH, recurrent UTI, dryness, urinary urgency and stress incontinence |
| Skin | Maintains dermal collagen and hyaluronic acid | Roughly 30% of skin collagen is lost in the first five post-menopausal years |
Read that table as a single argument. The ovary is an endocrine gland whose products maintain the skeleton, the vasculature, the lipid profile, the fat distribution, and the thermoregulatory set point. When it stops, seven systems change at once — which is why menopause is not a gynecological event with systemic side effects, but a systemic endocrine event that happens to be announced gynecologically.
Case File question 3, answered: what FSH is responding to
Amara's FSH of 24 mIU/mL is not a pituitary problem. It is the pituitary working correctly, in response to a signal that has stopped arriving.
Recall the male axis in §27.3: two feedback signals, one for each arm. The female axis works the same way. Inhibin B, secreted by the granulosa cells of small growing antral follicles, is the selective negative feedback signal on FSH. Estradiol is the general one.
Now apply §27.5's inventory. Amara's follicular pool has been depleted by five decades of atresia. The number of small growing follicles has fallen, so:
fewer small antral follicles
↓
LESS INHIBIN B secreted (this happens FIRST, and earliest)
↓
FSH is DISINHIBITED → FSH RISES
↓
higher FSH drives the few remaining follicles harder and earlier
↓
the follicular phase SHORTENS (cycles of 24–26 days — the earliest
↓ clinical sign of perimenopause)
eventually too few follicles respond at all
↓
cycles become ANOVULATORY and IRREGULAR; estradiol becomes erratic
(sometimes high, sometimes low); progesterone is often absent
↓
FSH rises further; AMH falls toward zero; menopause
This is exactly Chapter 16's localization rule: a high tropic hormone with a low or failing target hormone means primary failure of the target gland. High FSH plus low AMH plus erratic estradiol equals a normal pituitary shouting at an ovary that cannot answer. Amara's AMH of 0.3 ng/mL is the corroborating measurement, because AMH comes from those same small growing follicles and does not depend on gonadotropins at all.
Two clinical footnotes. FSH is a poor single test in perimenopause because it fluctuates enormously from cycle to cycle — a normal value proves nothing, and the diagnosis is clinical, made from the pattern of cycles and symptoms. And note that Amara's cycles being sometimes shorter is not a contradiction: shortened follicular phases come early in the transition, and irregularity and skipped cycles come later.
Case File question 1, answered: why cardiovascular risk changes
Take the estrogen table above and delete the estrogen. Amara's numbers over eighteen months are the prediction, measured:
| Three years ago | Now | Consistent with | |
|---|---|---|---|
| LDL cholesterol | 118 mg/dL | 148 mg/dL | Loss of hepatic LDL receptor upregulation |
| HDL cholesterol | 46 mg/dL | 38 mg/dL | Loss of apoA-I stimulation |
| Triglycerides | 190 mg/dL | 244 mg/dL | Visceral redistribution plus insulin resistance |
| Total cholesterol | 198 mg/dL | 232 mg/dL | The sum of the above |
Add what the panel does not show: reduced endothelial nitric oxide, so less vasodilation, more platelet adhesion, and more smooth muscle proliferation; rising arterial stiffness; a shift of body fat from gluteofemoral to visceral, which worsens the insulin resistance already documented in Chapter 16; and rising blood pressure. Every one of these is an independent cardiovascular risk factor, and they arrive together.
The epidemiology matches the mechanism. Women's cardiovascular event rates lag men's by roughly a decade, and that gap narrows after menopause. Longitudinal studies of the menopause transition show LDL, apolipoprotein B, visceral fat, and arterial stiffness worsening faster during the transition than chronological aging alone predicts. Early menopause (before 45) and premature ovarian insufficiency (before 40) are independently associated with higher cardiovascular risk.
Three honest qualifications, because this is an area where oversimplification has caused real harm:
- Estrogen loss is one contributor among several. Aging, weight gain, and rising blood pressure occur over the same years. The transition accelerates a trend; it does not create it from nothing.
- Hormone therapy is not a cardiovascular preventive. The evidence supports a "timing" pattern — therapy started within ten years of the final menstrual period or before age 60 has a broadly neutral-to-favourable cardiovascular profile, while therapy started later does not and may harm. Hormone therapy is prescribed for symptoms and for bone protection in appropriate candidates, with an individualized assessment of risk. It is not a substitute for treating lipids and blood pressure.
- Amara's risk was already high. She has diabetes, hypertension, obesity, chronic kidney disease, and an infarct. Menopause is being added to a stack, and the practical consequence is simply that her lipid and blood pressure targets should be reassessed now rather than at her next routine visit — which is exactly what her cardiologist's one-sentence note was for.
Aging · Menopause System by System, and the Male Comparison
Menopause is defined retrospectively: twelve consecutive months of amenorrhea with no other cause. Median age is about 51, with a normal range of 45–55; before 45 it is called early menopause and before 40, premature ovarian insufficiency. The perimenopause — the transition — lasts a median of about four years.
| System | Change after the final menstrual period |
|---|---|
| Skeletal | Rapid trabecular loss, ~2%/year for 5–8 years, then slower. Lifetime fracture risk approaches 50% in white women. Vertebrae and distal radius first — the trabecular-rich sites (Chapter 6) |
| Cardiovascular | Adverse lipid shift, rising arterial stiffness and blood pressure, reduced endothelial NO |
| Metabolic | Visceral fat gain, worsening insulin sensitivity, higher rate of new type 2 diabetes |
| Urogenital | Vaginal atrophy and rising pH, recurrent UTI, urgency, stress incontinence; responds well to topical estrogen |
| Thermoregulatory | Hot flushes in ~75%, median duration 7 years (longer if they begin early in the transition) |
| Neurological / sleep | Sleep fragmentation, partly from night sweats; transient verbal memory changes that generally resolve |
| Integumentary | ~30% of dermal collagen lost in the first five years |
Andropause is not the same phenomenon, and the difference is instructive. Testosterone falls by roughly 1% per year from the fourth decade, and sex hormone-binding globulin rises, so free testosterone falls faster than total. But the decline is gradual, partial, highly variable between individuals, and — critically — spermatogenesis continues, so fertility persists (with a rising rate of new mutations with paternal age). There is no abrupt cessation, no equivalent of the final menstrual period, and no universal symptom cluster. The correct term is late-onset hypogonadism, diagnosed only from consistent symptoms plus two low morning total testosterone measurements, because a single value is unreliable.
The prostate, meanwhile, does the opposite of shrinking. Benign hyperplasia of the transition zone begins around 40 and is present histologically in more than half of men by 60 and about 90% by 85 (§27.10) — which is why aging in men produces a urinary problem where aging in women produces a skeletal and vascular one.
Check Your Understanding 27.8
- A 43-year-old woman has hot flushes and an FSH of 40 mIU/mL, but a normal estradiol of 95 pg/mL. Is this consistent with perimenopause? Explain.
- Why does a woman with a uterus who takes estrogen-only hormone therapy need a progestin added, while a woman who has had a hysterectomy does not?
- Predict what happens to a man's bone density if he takes an aromatase inhibitor long-term, and explain why.
Show answers
- Yes, entirely consistent. In perimenopause, FSH rises early because inhibin B from the dwindling pool of small antral follicles falls — but estradiol is produced by whichever follicles are growing, and under a high FSH drive those follicles can produce normal or even supra-normal estradiol. The hallmark of the transition is therefore erratic estradiol alongside a persistently raised FSH, not uniformly low estradiol. This is why a single hormone panel cannot diagnose or exclude perimenopause, and why the diagnosis rests on the pattern of cycles and symptoms. It also explains why some women have symptoms of estrogen excess (breast tenderness, heavy bleeding) and estrogen deficiency (flushes) in alternating months.
- Because unopposed estrogen drives endometrial proliferation without the secretory transformation and coordinated shedding that progesterone produces. Sustained proliferation without differentiation leads to endometrial hyperplasia and, over years, to endometrial carcinoma; the risk rises several-fold. A progestin opposes this by inducing secretory change and either a regular withdrawal bleed or endometrial atrophy, depending on the regimen. A woman without a uterus has no endometrium to protect, so the progestin has no target and would only add side effects. The same logic explains the endometrial cancer risk in polycystic ovary syndrome and in obesity, where anovulation or adipose aromatase produce estrogen with little or no progesterone.
- Bone density falls. Aromatase converts testosterone to estradiol, and it is estradiol, not testosterone, that is the principal bone-preserving steroid in men as well as women — it restrains osteoclasts and it is what closes the epiphyses at the end of puberty. Blocking aromatase removes that protection while leaving androgen levels intact, so bone resorption accelerates. The natural experiments confirm it: men with congenital aromatase deficiency or inactivating estrogen receptor mutations have normal or high testosterone, unfused epiphyses, continued growth into adulthood, and osteoporosis. This is why aromatase inhibitors used therapeutically require bone density monitoring.
27.9 The Reproductive Lifespan
Puberty: reawakening a switch that was already there
Puberty is not the start of the reproductive axis. The GnRH pulse generator is active in fetal life and again in the first months after birth — a period called minipuberty, during which infant gonadotropins and sex steroids briefly reach near-pubertal levels. It is then actively restrained throughout childhood, and puberty is its release.
The switch is the kisspeptin system. Kisspeptin-producing neurons in the arcuate and anteroventral periventricular nuclei of the hypothalamus signal through the KISS1R receptor to GnRH neurons; loss-of-function mutations in either gene cause congenital hypogonadotropic hypogonadism with complete absence of puberty, and activating mutations cause central precocious puberty. Two further inputs gate the switch:
- Metabolic. Leptin, secreted by adipose tissue in proportion to fat mass, is permissive — the axis will not run without a signal that energy stores are adequate. This is why leptin deficiency prevents puberty, why obesity is associated with earlier puberty in girls, and why the functional hypothalamic amenorrhea of the Exercise sidebar below is, at bottom, an energy problem.
- Genetic and epigenetic. Loss of the brake gene MKRN3 causes precocious puberty; heritability accounts for much of the variation in pubertal timing.
The sequence, which is fixed even though the timing is not
In girls: thelarche (breast budding, ~10–11) is usually first, often with or shortly after adrenarche (adrenal androgen-driven pubic and axillary hair, which is a separate, independently timed process). The growth spurt comes early in the sequence, and menarche comes late — typically 2–2.5 years after thelarche, at a median of about 12.5, and after peak height velocity has passed. That ordering is why a girl who has already had her first period has usually completed most of her growing. Cycles are often anovulatory and irregular for the first 12–18 months, because the positive feedback switch of §27.6 takes time to mature.
In boys: testicular enlargement past 4 mL is the first sign (~11–12), followed by pubarche, penile growth, the growth spurt (peaking ~2 years later than in girls, around 13.5–14), voice change from laryngeal growth, and facial hair last. The later, longer growth period, on a larger androgen-driven skeletal frame, accounts for most of the adult height difference between the sexes.
Both sequences are staged with the Tanner scale (stages 1–5), which rates breast and genital development and pubic hair separately, precisely because they are driven by different hormones from different glands.
And in both sexes, estradiol closes the epiphyses. The growth spurt is driven by sex steroids acting with growth hormone and IGF-1; its termination is estrogen's doing (Chapter 6). In boys that estrogen comes from aromatization of testosterone. This is one of the cleanest examples in endocrinology of the same hormone both starting and stopping a process, at different concentrations and at a different point in the sequence.
Exercise & Sport · RED-S, Functional Hypothalamic Amenorrhea, and What the Cycle Data Actually Show
Low energy availability is the primary lesion. Energy availability is dietary energy intake minus exercise energy expenditure, normalized to fat-free mass. Below roughly 30 kcal per kg of fat-free mass per day, the hypothalamus responds as it would to famine: GnRH pulse frequency falls, LH pulsatility becomes disordered, FSH and estradiol fall, and cycles become anovulatory and then absent. This is functional hypothalamic amenorrhea — "functional" because nothing is structurally wrong, and the axis recovers when energy availability is restored.
Note that this is not caused by exercise, body fat percentage, or "the stress of competition" as such. It is caused by the energy deficit, whether that deficit arises from eating too little, training too much, or both. Leptin, insulin, IGF-1, and ghrelin all shift with energy availability and all feed into the kisspeptin gate; cortisol rises and adds a further suppressive signal. An athlete can be amenorrheic at a perfectly ordinary body weight if her intake does not match her output.
The bone consequence is the serious one, and it is not reversible. Estrogen restrains osteoclasts (§27.8). Remove it during the years when peak bone mass is being accumulated — roughly ages 12 to 25, with about 90% of adult bone mass laid down by 18 — and the athlete does not merely lose bone; she fails to build it. Consequences: stress fractures during the athletic career (especially at trabecular-rich sites), and a permanently lower peak bone mass that raises fracture risk for the rest of her life. Some of the deficit persists even after menses return and weight is restored, which is why this is a condition to prevent rather than to treat.
The female athlete triad — low energy availability, menstrual dysfunction, low bone mineral density — was the original framing. RED-S (relative energy deficiency in sport) extends it, because the same energy deficit also impairs immune function, protein synthesis, cardiovascular health, gastrointestinal function, iron status, mood, and — the part athletes care about most — performance. The condition affects men too, by exactly the same hypothalamic mechanism (see the Anabolic Steroids sidebar, §27.3). Treatment is nutritional and behavioural: restore energy availability. Combined oral contraceptives will produce a withdrawal bleed and mask the warning sign without correcting the bone loss, because they do not fix the energy deficit.
Nia is the counterexample worth studying: she is a high-volume marathon runner with regular ovulatory cycles and a documented luteal temperature rise. Her axis is intact because her intake matches her training. A regular cycle in an endurance athlete is a vital sign.
What the evidence actually shows about performance across the cycle. This is an area where the popular claims run far ahead of the data, so be precise about three things.
- Group-level effects are small and inconsistent. Systematic reviews of cycle-phase effects on strength, endurance, and power find, on average, a trivial reduction in performance in the early follicular phase (when both estradiol and progesterone are low) — but with wide confidence intervals, high heterogeneity, and generally low-quality study designs. The average effect is smaller than day-to-day variation from sleep, nutrition, and training load.
- Individual effects can be large. A meaningful minority of athletes report substantial, reproducible symptom-driven decrements — from dysmenorrhea, heavy bleeding, or premenstrual symptoms — that plainly affect training quality. Those are real and treatable, and they are a better target than phase-based periodization.
- The physiologically well-established changes are the ones in Nia's log: a luteal rise in core temperature of 0.3–0.5 °C, a modest rise in resting heart rate, a small rise in resting metabolic rate, progesterone-driven hyperventilation with a lower arterial PCO₂, and slightly greater cardiovascular strain during exercise in the heat because thermoregulation starts from a higher set point. Those are physiology; the performance implications remain modest.
The defensible practical position: track the cycle, treat the symptoms, and individualize — rather than prescribing phase-based training programmes from group averages that barely differ.
Menopause, and its male non-equivalent
Both are covered in the Aging sidebar in §27.8. The one structural point to add here is the STRAW+10 staging system, which divides the reproductive lifespan into reproductive, menopausal-transition, and post-menopausal stages using cycle characteristics as the primary criterion and FSH and AMH as supporting criteria. Its existence is an admission of the point made in §27.8: no single hormone measurement diagnoses this transition, because the transition is defined by variability, and a single measurement cannot show variability.
27.10 Advanced Topic · Selected Conditions as Physiology
Each of the conditions below is chosen because understanding the physiology is understanding the disease. None of them is a list to memorize.
THE HPG AXIS IN BOTH SEXES — same architecture, one crucial difference
┌──────────── MALE ────────────┐ ┌────────── FEMALE ────────────┐
│ HYPOTHALAMUS │ │ HYPOTHALAMUS │
│ GnRH pulses q90–120 min │ │ GnRH pulses; FREQUENCY │
│ STEADY, unvarying │ │ VARIES BY PHASE │
│ │ │ │ │ │
│ ▼ │ │ ▼ │
│ ANTERIOR PITUITARY │ │ ANTERIOR PITUITARY │
│ LH FSH │ │ LH FSH │
│ │ │ │ │ │ │ │
│ ▼ ▼ │ │ ▼ ▼ │
│ LEYDIG SERTOLI │ │ THECA GRANULOSA │
│ cell cell │ │ INTERNA cell │
│ │ │ │ │ │ │ │
│ │ ├─► ABP │ │ │ andro- │ AROMATASE │
│ │ ├─► sperm │ │ └─stene-───►│ ▼ │
│ ▼ ▼ │ │ dione │ ESTRADIOL │
│ TESTOSTERONE INHIBIN B │ │ │ INHIBIN B │
│ │ │ │ │ │ │ │
│ │ (−) │ (−) FSH │ │ │ │ (−) │
│ │ GnRH+LH │ ONLY │ │ │ │ FSH │
│ └──────┐ ┌───┘ │ │ │ │ ONLY │
│ ▼ ▼ │ │ ┌───────┘ │ │
│ ═══ NEGATIVE ═══ │ │ │ │ │
│ FEEDBACK ONLY │ │ ▼ ▼ │
│ no cycle · no surge │ │ ┌──────────────────────────┐│
│ steady state for │ │ │ ESTRADIOL FEEDBACK ││
│ ~60 years │ │ │ < 200 pg/mL → NEGATIVE ││
│ │ │ │ > 200 pg/mL for 36–48 h ││
│ │ │ │ → ★ POSITIVE ★ ││
│ │ │ │ → LH SURGE ││
│ │ │ │ → OVULATION ││
│ │ │ └──────────────────────────┘│
│ │ │ then CORPUS LUTEUM → │
│ │ │ PROGESTERONE + INHIBIN A │
│ │ │ → strong NEGATIVE feedback │
│ │ │ → loop RESET, 28-day CYCLE │
└──────────────────────────────┘ └──────────────────────────────┘
IDENTICAL: hypothalamus → pituitary → gonad; two gonadotropins; two
feedback signals (a steroid for the hormone arm, INHIBIN for the
gamete arm); pulsatile GnRH required in both.
DIFFERENT: the female axis contains a THRESHOLD-DEPENDENT SIGN
REVERSAL. That single feature converts a steady-state controller
into an oscillator — and an oscillator is what releasing ONE gamete
at ONE moment requires.
Figure 27.7 — The hypothalamic-pituitary-gonadal axis in both sexes, showing where the feedback differs.
Described: Two side-by-side diagrams of the hypothalamic-pituitary-gonadal axis. On the left, the male axis: the hypothalamus releases GnRH in steady pulses every 90 to 120 minutes; the anterior pituitary releases LH and FSH; LH acts on Leydig cells to produce testosterone, and FSH acts on Sertoli cells, which produce androgen-binding protein, support sperm production, and secrete inhibin B. Testosterone exerts negative feedback on both GnRH and LH, while inhibin B selectively inhibits FSH only. The system is labeled as negative feedback only, with no cycle and no surge, running at steady state for about sixty years. On the right, the female axis: the hypothalamus releases GnRH in pulses whose frequency varies by cycle phase; the pituitary releases LH and FSH; LH acts on theca interna cells to make androstenedione, which diffuses into granulosa cells where FSH-induced aromatase converts it to estradiol, and granulosa cells also secrete inhibin B, which selectively inhibits FSH. The crucial difference is boxed: estradiol below about 200 picograms per millilitre exerts negative feedback, but estradiol above that threshold sustained for 36 to 48 hours exerts positive feedback, producing the LH surge and ovulation. Afterwards the corpus luteum secretes progesterone and inhibin A, restoring strong negative feedback and resetting the loop for a 28-day cycle. A summary states that the two axes are identical in architecture — a three-tier axis, two gonadotropins, two feedback signals consisting of a steroid for the hormone arm and an inhibin for the gamete arm, and a requirement for pulsatile GnRH — and differ in exactly one respect: the female axis contains a threshold-dependent reversal of feedback sign, which converts a steady-state controller into an oscillator, and an oscillator is what releasing one gamete at one moment requires.
Clinical Connection · Polycystic Ovary Syndrome Is a Metabolic Disease Wearing Gynecological Clothes
PCOS affects 8–13% of women of reproductive age and is the commonest cause of anovulatory infertility. Diagnosis uses the Rotterdam criteria — any two of three, after excluding mimics: (1) oligo- or anovulation; (2) clinical or biochemical hyperandrogenism; (3) polycystic ovarian morphology on ultrasound (20 or more follicles of 2–9 mm per ovary, or ovarian volume ≥ 10 mL).
The name is unfortunate. The "cysts" are not cysts — they are arrested antral follicles, a crowd of 2–9 mm follicles none of which achieves dominance. Understanding why they arrest is understanding the disease, and the path runs through Chapter 24.
INSULIN RESISTANCE (independent of, but worsened by, adiposity)
↓
COMPENSATORY HYPERINSULINEMIA
↓
┌────────────────┬─────────────────────┬──────────────────────┐
│ THECA cells │ LIVER │ PITUITARY │
│ remain INSULIN │ insulin SUPPRESSES │ altered GnRH pulse │
│ SENSITIVE for │ sex hormone-binding │ frequency raises the │
│ steroidogenesis│ globulin (SHBG) │ LH : FSH ratio │
│ ↓ │ ↓ │ ↓ │
│ ↑ ANDROGEN │ ↑ FREE testosterone │ ↑ LH drives theca; │
│ production │ (same total, more │ relatively ↓ FSH │
│ │ bioavailable) │ starves granulosa │
└────────┬───────┴──────────┬──────────┴──────────┬───────────┘
└──────────────────┴─────────────────────┘
↓
HYPERANDROGENISM + HIGH AMH from the large antral pool
↓
FOLLICLES ARREST AT 2–9 mm — no dominant follicle selected
↓
ANOVULATION → no corpus luteum → NO PROGESTERONE
↓
UNOPPOSED ESTROGEN → endometrial hyperplasia risk
Note the beautiful and unpleasant selectivity in the first box: muscle and liver become resistant to insulin's metabolic actions while the ovarian theca cell stays fully sensitive to insulin's steroidogenic action. The hyperinsulinemia that fails to lower blood glucose succeeds magnificently at raising androgen production. This is the same pathophysiology Amara carries (fasting insulin 28 µU/mL, Chapter 16) expressed in a different tissue.
Treatment maps cleanly onto the diagram. Weight loss and metabolic therapy (dietary change, metformin, GLP-1 receptor agonists) attack the top of the cascade and can restore ovulation. Combined hormonal contraception suppresses LH, raises SHBG, and protects the endometrium from unopposed estrogen — treating three arms at once, though not the insulin resistance. Letrozole, an aromatase inhibitor, is now first-line for ovulation induction: by blocking the conversion of androgen to estradiol it lowers estrogen feedback, so FSH rises and a dominant follicle is finally selected. And anti-androgens (spironolactone) treat hirsutism. Long term, the conversation that matters is not about the ovaries: it is about the substantially raised lifetime risk of type 2 diabetes, dyslipidemia, and cardiovascular disease.
Clinical Connection · Endometriosis, and the Anatomical Gap That Permits It
Endometriosis is the presence of endometrial-like glands and stroma outside the uterus, affecting about 10% of women of reproductive age and up to 50% of those with infertility or chronic pelvic pain.
How does uterine tissue get into the pelvis? The dominant explanation, retrograde menstruation, invokes the anatomical fact from §27.4: the uterine tubes open into the peritoneal cavity, so menstrual debris can and does flow backwards. But retrograde menstruation occurs in most women and endometriosis occurs in about one in ten, so reflux alone is insufficient. The contributing factors are impaired immune clearance of refluxed cells, coelomic metaplasia of peritoneal mesothelium, and altered stem cell behaviour.
Why it hurts. The ectopic tissue is estrogen-responsive and — crucially — expresses its own aromatase, so it manufactures estrogen locally and is partly self-sustaining. It responds to the cycle by proliferating and bleeding, but it bleeds into closed spaces where there is no drainage. The result is repeated inflammation, fibrosis, dense adhesions, and, in the ovary, blood-filled "chocolate cysts" (endometriomas). The lesions recruit new nerve fibres (neuroangiogenesis) and, over years, drive central sensitization, which is why pain severity correlates poorly with the visible extent of disease and why pain can persist after the lesions are removed.
The symptom cluster — secondary dysmenorrhea, deep dyspareunia, dyschezia, cyclical bowel or bladder symptoms, chronic pelvic pain, and subfertility — is characteristic. Yet the mean delay from first symptom to diagnosis is seven to ten years, largely because severe menstrual pain is normalized. Treatment follows the physiology: suppress cyclical estrogen exposure (combined hormonal contraception used continuously, progestins, a levonorgestrel IUD, or GnRH analogues with add-back therapy), excise or ablate lesions surgically, and treat the pain as pain in its own right once sensitization has developed.
Clinical Connection · Benign Prostatic Hyperplasia — Anatomy Producing an Obstruction
The prostate has zones, and the two that matter behave differently.
- The transition zone immediately surrounds the prostatic urethra. It is where benign hyperplasia grows.
- The peripheral zone forms the bulk of the posterior gland, closest to the rectum. About 70% of prostate cancers arise here.
That single anatomical fact explains four clinical observations at once: benign enlargement obstructs urine flow while early cancer usually does not; a digital rectal examination palpates the peripheral zone and therefore detects cancer rather than hyperplasia; a man can have a very large obstructing prostate and no cancer; and a man can have a normal-sized gland and a significant tumour.
BPH is DHT-dependent, developing in the presence of androgens over time: histological changes appear from about age 40, are present in more than half of men by 60 and roughly 90% by 85. The consequence chain is worth tracing in full, because it ends in Chapter 26:
transition zone enlarges → compresses the prostatic urethra
→ increased outflow resistance
→ DETRUSOR must generate higher pressure → hypertrophy
→ hypertrophied detrusor becomes IRRITABLE and unstable
├─► STORAGE symptoms: frequency, urgency, NOCTURIA
└─► VOIDING symptoms: hesitancy, weak stream, dribbling,
incomplete emptying
→ post-void RESIDUAL urine (stasis)
├─► recurrent urinary tract INFECTION
├─► bladder STONES
└─► eventually bilateral HYDRONEPHROSIS
→ POSTRENAL acute kidney injury (§26.10)
Treatment is a two-speed strategy that follows the two components of the obstruction. α₁-adrenergic blockers (tamsulosin) relax the smooth muscle of the prostate stroma and bladder neck — the same α₁ receptors that maintain the internal urethral sphincter during storage (§26.9) — and work within days, addressing the dynamic component. 5α-reductase inhibitors (finasteride, dutasteride) block conversion of testosterone to DHT and shrink the gland by 20–30% over 6–12 months, addressing the static component. One practical consequence worth knowing: 5α-reductase inhibitors roughly halve serum PSA, so a man taking one must have his PSA result doubled before it is interpreted.
Clinical Connection · Infertility, and Contraception, on the Same Diagram
Infertility — no conception after 12 months of regular unprotected intercourse (6 months if the female partner is over 35) — affects about 15% of couples. The causes distribute roughly as: male factor 35%, ovulatory disorders 25%, tubal and pelvic factors 20%, unexplained 15%, and uterine or cervical factors 5%, with substantial overlap.
The workup is designed around the cycle figure, cheapest and least invasive first:
| Question | Test | What it reads off Figure 27.6 |
|---|---|---|
| Are there sperm? | Semen analysis | Panel C's male equivalent; done first because it is cheap and non-invasive |
| Is she ovulating? | Mid-luteal progesterone (7 days before the expected period), > 3 ng/mL confirms ovulation | Panel B's luteal progesterone rise |
| How many follicles are left? | AMH and antral follicle count | Panel C's recruitable cohort |
| Are the tubes open? | Hysterosalpingography | Transport, not hormones |
| Is the uterus normal? | HSG, saline sonography, or hysteroscopy | Panel D's endometrium |
Treatments then map onto the same panels. Letrozole or clomiphene lower estrogen feedback so that FSH rises and a follicle is selected (Panel A). Gonadotropin injections override selection entirely. Intrauterine insemination bypasses the cervix. IVF bypasses the tubes; ICSI bypasses the sperm's own capacity to penetrate the oocyte.
Contraception is the same figure, read for where to interrupt it:
| Method | Where it acts | Primary mechanism |
|---|---|---|
| Combined estrogen–progestin (pill, patch, ring) | Panels A and B | Suppresses FSH so no cohort is recruited; prevents the estradiol threshold from triggering the LH surge; plus thick mucus and thin endometrium |
| Progestin-only pill | Panel D and cervix | Thickens cervical mucus, thins endometrium; inconsistently suppresses ovulation |
| Implant / injectable (DMPA) | Panels A, B, D | Higher progestin exposure does suppress ovulation, plus mucus and endometrial effects |
| Levonorgestrel IUD | Panel D, locally | Endometrial atrophy and mucus thickening; ovulation usually continues |
| Copper IUD | Gamete transport | Copper ions are directly toxic to sperm and ova; a sterile inflammatory reaction in the endometrium. Non-hormonal |
| Emergency levonorgestrel | Panel A | Delays or prevents the LH surge. Ineffective once the surge has started — which is why timing matters so much |
| Ulipristal acetate | Panel A | Selective progesterone receptor modulator; can delay the surge even after LH has begun to rise, so it has a wider effective window |
| Vasectomy / tubal occlusion | Transport | Mechanical interruption of the duct |
| Fertility awareness | Panels B and E | Identifies the fertile window — approximately the six days ending on ovulation, because sperm survive up to five days in fertile cervical mucus and the oocyte survives 12–24 hours. Cervical mucus and urinary LH predict; basal body temperature only confirms afterwards (§27.7) |
The last row is the reason the temperature method alone is unreliable for avoiding pregnancy: by the time the temperature rises, the fertile window has already closed.
Histology · Reading the Endometrium — Proliferative versus Secretory
A pathologist can date an endometrial biopsy to within a day or two of the cycle, using features that follow directly from §27.7's hormones.
| Feature | Proliferative (estrogen) | Secretory (progesterone) |
|---|---|---|
| Glands | Narrow, straight, tubular, evenly spaced | Wide, coiled and tortuous, sawtooth outline |
| Gland lumen | Empty | Filled with eosinophilic secretion |
| Glandular cells | Pseudostratified nuclei; frequent mitoses | Single layer; subnuclear glycogen vacuoles appear on days 16–18, then move to a supranuclear position |
| Stroma | Dense, compact, spindled | Edematous early, then decidualized: plump, pale, polygonal cells |
| Spiral arteries | Elongating, inconspicuous | Prominent, tightly coiled, surrounded by decidualized stroma |
| Thickness | 4–10 mm, increasing | 10–14 mm, stable |
Two features are worth learning as single-glance markers. Mitotic figures in the glandular epithelium mean estrogen is acting without progesterone — proliferative phase, or, if seen in a post-menopausal biopsy, unopposed estrogen and a reason to look hard for hyperplasia. Subnuclear vacuoles — clear glycogen spaces lined up between the nucleus and the basement membrane — are the first histological evidence that ovulation has occurred, appearing about 36–48 hours after it. A biopsy showing them is proof of a corpus luteum, which is why endometrial dating was for decades used as an ovulation test.
The stroma tells you the phase too: compact and spindled under estrogen, edematous and then plump and decidualized under progesterone. That decidual change is the beginning of the implantation bed, which is where Chapter 28 picks up the story.
Chapter Summary
§27.1 Both reproductive systems have gonads, ducts, accessory glands, and external genitalia, and both are built from one embryonic plan. The bipotential gonad is colonized by primordial germ cells; SRY drives it toward testis, whereupon Sertoli cells secrete anti-Müllerian hormone (destroying the paramesonephric ducts) and Leydig cells secrete testosterone (preserving the mesonephric ducts). Without SRY, an active ovarian program runs and the Müllerian ducts persist. Male differentiation therefore requires two positive signals, which is why it has more ways to fail. Homologous structures follow from the shared origin.
§27.2 The testis is divided by the tunica albuginea into lobules containing roughly 250 metres of seminiferous tubule, with Leydig cells between them. Spermatogenesis requires 34 °C, maintained by three cooperating structures: the dartos (variable surface area), the cremaster (variable distance), and the pampiniform plexus, a countercurrent heat exchanger using the same physics as the vasa recta. Sperm mature in the epididymis over 12–20 days. Accessory glands supply 95% of semen: seminal vesicles (fructose, prostaglandins, clotting protein), prostate (citrate, zinc, PSA to liquefy the coagulum), and bulbourethral glands. Erection is parasympathetic and nitric-oxide-mediated; emission and ejaculation are sympathetic and somatic.
§27.3 Spermatogenesis proceeds from spermatogonium through primary and secondary spermatocytes to four spermatids, which are then remodeled without division during spermiogenesis; the whole process takes 64–72 days and is arranged in space from basement membrane to lumen. Sertoli cells form the blood-testis barrier, nourish and phagocytose, secrete androgen-binding protein and inhibin B. The male axis is pure negative feedback with two signals: testosterone inhibits GnRH and LH; inhibin B selectively inhibits FSH. Testosterone acts directly on muscle, marrow, and ducts, through DHT on the prostate, external genitalia, and hair, and through estradiol on bone — including epiphyseal closure in both sexes.
§27.4 The ovary is not continuous with the uterine tube, so the oocyte crosses the peritoneal cavity — the anatomical basis of ectopic pregnancy and endometriosis. Fertilization occurs in the ampulla. The uterus has perimetrium, myometrium, and an endometrium divided into a shed stratum functionalis and a permanent stratum basalis, supplied respectively by progesterone-sensitive spiral arteries and hormone-insensitive straight arteries — which is the mechanical explanation of menstruation. Vaginal pH of 3.5–4.5 is estrogen-dependent, via glycogen and lactobacilli.
§27.5 The oocyte pool peaks at 6–7 million before birth and is drawn down by atresia to about 400 ovulations. Oocytes arrest in prophase I for decades (explaining maternal age-related aneuploidy) and again in metaphase II until fertilization. Follicles progress from primordial through primary, secondary, and antral to Graafian, then become corpus luteum and corpus albicans; the whole journey takes about a year, and only the last two weeks are gonadotropin-dependent. Estrogen synthesis requires two cells and two gonadotropins.
§27.6 FSH rises when inhibin and steroids fall, recruits a cohort, and the dominant follicle wins by suppressing the FSH its rivals need. Above about 200 pg/mL sustained for 36–48 hours, estradiol's feedback switches from negative to positive, producing the LH surge and ovulation 36 hours later. This is the only sign reversal in endocrinology, and — like every safe positive loop — it terminates by consuming its own stimulus. The corpus luteum's fixed 14-day lifespan means cycle-length variation lives entirely in the follicular phase.
§27.7 The uterine cycle runs menstrual, proliferative (estrogen), and secretory (progesterone) phases. Estrogen installs the progesterone receptor; cervical mucus reverses twice a cycle. Menstruation is a controlled infarction: progesterone withdrawal → spiral artery spasm → ischemic necrosis → reperfusion through damaged vessels → shedding, with the basalis protected on a separate circulation. Progesterone raises the hypothalamic set point by 0.3–0.5 °C, producing the luteal temperature plateau — a set-point shift, exactly like fever.
§27.8 Estrogen acts on bone (restrains osteoclasts), endothelium (raises nitric oxide), liver (raises LDL receptors and apoA-I), adipose (favours subcutaneous over visceral fat), brain (stabilizes the thermoneutral zone), and urogenital tissue. Perimenopause is ovarian failure, not pituitary failure: falling follicle numbers mean falling inhibin B, so FSH is disinhibited and rises. Losing estrogen's vascular and lipid protection is a genuine change in cardiovascular risk, though one contributor among several.
§27.9 Puberty is the release of a restrained GnRH pulse generator, gated by kisspeptin and permitted by leptin. Sequences are fixed even where timing varies: thelarche then menarche late in girls; testicular enlargement first in boys. Estradiol closes the epiphyses in both. Menopause is abrupt and universal; the male decline is gradual, partial, and variable.
§27.10 PCOS is insulin resistance expressed through a still-insulin-sensitive theca cell. Endometriosis is estrogen-responsive tissue in the peritoneum, permitted by the open female tract. BPH is transition-zone growth compressing a urethra, ending in a urinary problem that reaches the kidney. Contraception and infertility treatment are both read off the same cycle diagram — one interrupting it, the other restoring it.
The Three Threads in Chapter 27
Structure → Function. The two gametes are opposite solutions to two halves of one problem: one is a stripped-down delivery vehicle, the other a fully provisioned workshop. The pampiniform plexus is a countercurrent heat exchanger built for exactly the reason the vasa recta is a countercurrent solute exchanger. The corpus cavernosum has a stiff tunica because it must become rigid; the corpus spongiosum has a compliant one because there is a tube inside it. And the endometrium's split blood supply — hormone-sensitive spiral arteries above, insensitive straight arteries below — is what makes a tissue that can be destroyed and rebuilt forty times a year for forty years.
Homeostasis. This is the one chapter where the master concept bends. Almost everything in this book is negative feedback; the female cycle contains a threshold-dependent reversal of sign, and that single feature converts a steady-state controller into an oscillator. It is safe for the same reason clotting and labor are safe — it terminates by destroying its own stimulus. Everything else in the chapter is orthodox: two feedback signals per axis, one for the hormone arm and one for the gamete arm, and a set point (temperature) that a hormone can deliberately move.
Integration. The gonads are endocrine glands whose products maintain the skeleton, the endothelium, the lipid profile, fat distribution, and the thermoregulatory set point. That is why Amara's cardiologist wrote about her hormones, why Adwoa's fractured wrist began at a menopause thirty years ago, why Nia's resting heart rate moves on a 28-day schedule, and why RED-S in a 19-year-old athlete is a bone disease. The reproductive system is the least self-contained system in the book.
Case File 27 · Resolution
Question 1 — What does estrogen do to blood vessels and lipids, and why does losing it change cardiovascular risk?
Estrogen acts on the vasculature and the liver through receptors that have nothing to do with reproduction.
On blood vessels. Estradiol upregulates endothelial nitric oxide synthase and increases nitric oxide bioavailability, both through slow genomic effects at ERα and through rapid non-genomic signalling at the membrane receptor GPER. More nitric oxide means more vasodilation, less platelet adhesion, less vascular smooth muscle proliferation, and less expression of the adhesion molecules that recruit monocytes into the vessel wall — the first step of an atherosclerotic plaque (Chapter 19). Estrogen is also antioxidant and limits LDL oxidation. Withdraw it and flow-mediated dilation falls, arterial stiffness rises measurably across the transition, and blood pressure drifts up.
On lipids. Estradiol increases hepatic LDL receptor expression, so the liver clears LDL from the blood faster; it increases apolipoprotein A-I synthesis, so HDL rises; and it modestly raises triglycerides. Withdraw it and the whole pattern reverses.
Amara's own numbers are that reversal, measured over eighteen months: LDL 118 → 148 mg/dL, HDL 46 → 38 mg/dL, triglycerides 190 → 244, total cholesterol 198 → 232. Add the changes the lipid panel does not report — a shift of fat from gluteofemoral to visceral depots, which worsens the insulin resistance already documented in Chapter 16; reduced endothelial nitric oxide; and rising arterial stiffness — and every element of her cardiovascular risk profile has moved in the wrong direction at once.
This is why women's cardiovascular event rates lag men's by roughly a decade and why that gap narrows after menopause, and why early menopause and premature ovarian insufficiency are independently associated with higher risk.
Three honest qualifications. Aging and weight gain occur over the same years, so the transition accelerates an existing trend rather than creating one. Hormone therapy is not a cardiovascular preventive — the evidence supports a timing pattern in which therapy begun within ten years of the final period is broadly neutral, and later initiation is not, and hormone therapy is prescribed for symptoms and bone protection rather than for the heart. And Amara's risk was already high from diabetes, hypertension, obesity, chronic kidney disease, and an infarct. The practical consequence of her cardiologist's note is not a hormone prescription; it is that her lipid and blood pressure targets should be reassessed now, because a risk factor has just been added to a stack that was already tall.
Question 2 — Why does the cycle change body temperature, and by how much?
By 0.3–0.5 °C (0.5–1.0 °F), beginning within 24–48 hours of ovulation and lasting until menstruation. Nia's log — 36.4 °C in the follicular phase, 36.8 °C in the luteal phase, a rise of 0.4 °C — sits exactly in that range.
The cause is progesterone, which appears only after ovulation, when the corpus luteum forms. Progesterone is thermogenic: acting on the hypothalamic thermoregulatory centre, largely through its neurosteroid metabolite allopregnanolone at warm-sensitive preoptic neurons, it raises the set point. It also raises resting metabolic rate by roughly 2–8%.
The important conceptual point is that this is a set-point shift, not a failure of thermoregulation — the same logic as fever in Chapter 1. Nothing is broken. No effector is underperforming. The thermostat has been deliberately moved, and the body then defends the new, higher target with entirely normal machinery. That is why the elevation is a stable plateau rather than a drift, and why it ends abruptly when progesterone falls.
Two consequences worth carrying. Because the rise follows ovulation, basal body temperature confirms ovulation retrospectively and cannot predict it — which is why temperature alone is a poor contraceptive method, and why urinary LH and cervical mucus are used to look forward. And a temperature plateau lasting beyond 16–18 days is one of the earliest signs of pregnancy: hCG has rescued the corpus luteum, progesterone has not fallen, and the set point has not come back down.
Nia's resting heart rate moves for related reasons: the higher core temperature itself raises heart rate by roughly 8–10 beats per minute per degree Celsius, progesterone raises metabolic rate, and progesterone is a respiratory stimulant that increases ventilation and lowers arterial PCO₂ by 2–4 mm Hg in the luteal phase. Her 52 → 57 beats per minute is predictable physiology, and an athlete who monitors resting heart rate without knowing her cycle phase will misread it as fatigue.
Question 3 — What is FSH responding to at 24 mIU/mL?
To an absence of inhibin B — that is, to an ovary that no longer has enough small growing follicles to send the signal that normally holds FSH down.
Recall the two-signal architecture of Figure 27.7. In both sexes, the gonad sends two feedback messages: a steroid reporting on the hormone-producing arm, and an inhibin reporting selectively on the gamete-producing arm. In the female, inhibin B comes from the granulosa cells of small antral follicles, and it is the specific brake on FSH.
Amara's follicular pool has been depleted by five decades of continuous atresia — an attrition that runs from mid-gestation onward and that nothing she did or did not do could change. Fewer small growing follicles means less inhibin B, so FSH is disinhibited and rises. Higher FSH then drives the remaining follicles harder and earlier, which is why the earliest clinical sign of the transition is a shortening of the follicular phase, giving cycles of 24–26 days. Eventually too few follicles respond at all: cycles become anovulatory and irregular, estradiol swings between high and low rather than falling steadily, progesterone is often absent altogether, and FSH climbs further.
So the finding is not a pituitary abnormality. It is Chapter 16's localization rule applied straightforwardly: a high tropic hormone with a failing target means primary failure of the target gland. Her pituitary is doing exactly what a normal pituitary does when the feedback stops arriving — shouting louder. The corroboration is her AMH of 0.3 ng/mL: AMH is secreted by those same small growing follicles at a stage that is entirely gonadotropin-independent, so it is close to a direct count of what remains, and it is unaffected by which day of the cycle the blood was drawn.
Two footnotes. FSH is a poor single test in perimenopause, because it fluctuates dramatically from cycle to cycle; a normal value on one day proves nothing, which is why the diagnosis is clinical and why staging systems use the pattern of cycles as the primary criterion. And the same mechanism explains her irregular bleeding: without ovulation there is no corpus luteum, without a corpus luteum there is no progesterone, and an endometrium exposed to erratic estrogen with no progesterone proliferates and sheds unpredictably rather than in the orderly, synchronized way described in §27.7.
Systems Integration Case File · Entry 27
Entry 27 — The gland nobody counted
New findings for your file. Amara, 45: cycles irregular for 18 months; FSH 24 mIU/mL, LH 14 mIU/mL, estradiol 38 pg/mL, AMH 0.3 ng/mL; 6–8 hot flushes daily; LDL 148 mg/dL (was 118), HDL 38 mg/dL (was 46), triglycerides 244 mg/dL, total cholesterol 232 mg/dL. Nia, 24: regular ovulatory cycles with a documented luteal temperature rise of 0.4 °C and a luteal resting heart rate 5 beats/min above her follicular baseline. Adwoa, 78: osteoporosis, menopause at 49.
Your entry:
1 · ADD. In two or three sentences, state what the reproductive system contributes to Amara's picture. Use at least three of her numbers, and be explicit about which organ has failed.
2 · CONNECT. Link the reproductive system to at least two systems already in your file, stating the direction of causation each time. At least one link must run to a system that is not cardiovascular.
3 · PREDICT. Nia becomes pregnant in Chapter 28. Predict one specific way her existing cardiovascular or renal physiology will be tested by pregnancy, and name the family history that makes it a real concern.
Show answers
1 · ADD. Amara is in the menopausal transition: her FSH of 24 mIU/mL with an AMH of 0.3 ng/mL and erratic estradiol shows a normal pituitary responding to a failing ovary, not a pituitary disorder. The failing organ is the ovary, and specifically its supply of small growing follicles, whose loss removes the inhibin B that normally restrains FSH. The consequence that matters clinically is not the flushes but the lipid shift over the same 18 months — LDL 118 to 148 mg/dL and HDL 46 to 38 mg/dL — which is the measurable withdrawal of estrogen's hepatic and vascular protection.
2 · CONNECT. Reproductive → cardiovascular: falling estradiol reduces hepatic LDL receptor expression and apoA-I synthesis (raising LDL, lowering HDL) and reduces endothelial nitric oxide synthase activity (reducing vasodilation and raising arterial stiffness), so her atherosclerotic risk rises on top of an already-infarcted heart. Reproductive → skeletal: estrogen loss removes the restraint on osteoclasts, so bone resorption accelerates at about 2% per year of trabecular bone — the pathway that produced Adwoa's osteoporosis thirty years earlier and that Amara has now entered. Reproductive → metabolic/endocrine: estrogen loss shifts fat storage from gluteofemoral to visceral depots, which worsens the insulin resistance documented in Chapter 16 (fasting insulin 28 µU/mL) and therefore her glycemic control. Reproductive → urinary: falling estrogen thins the vaginal and urethral epithelium and raises vaginal pH, increasing her risk of urinary tract infection — which matters more than usual in a woman with stage 3a chronic kidney disease (Chapter 26). Metabolic → reproductive (the reverse direction): her adiposity means adipose aromatase converts adrenal androgens to estrone, which is why some women with obesity have less abrupt symptoms but a higher endometrial cancer risk from unopposed estrogen.
3 · PREDICT. Pregnancy raises plasma volume by 40–50% and cardiac output by 30–50% while lowering systemic vascular resistance — a sustained volume and flow challenge to the heart and a 40–50% rise in GFR for the kidneys. Given that Nia's mother had hypertension and a myocardial infarction at 45, her grandmother has hypertension, and her maternal grandfather died of a myocardial infarction at 58, the specific concern is preeclampsia — a disorder of placental vascular development that presents as hypertension with proteinuria and is strongly predicted by family history of hypertension and cardiovascular disease. A defensible alternative is gestational diabetes, given the strong family history of insulin resistance. Both predictions are testable in Chapter 28, and both are examples of pregnancy acting as a stress test that reveals latent cardiovascular and metabolic risk decades before it would otherwise appear.
Review
Level 1 · Recall
23.1 Anti-Müllerian hormone in the male fetus is secreted by:
a) Leydig cells b) Sertoli cells c) the anterior pituitary d) spermatogonia
Answer
b — Sertoli cells. They differentiate first under SRY and SOX9 and secrete AMH, which causes the paramesonephric (Müllerian) ducts to regress. Leydig cells (a) secrete the other required signal, testosterone, which preserves the mesonephric ducts — two different cells, two different hormones, two opposite jobs.
23.2 Fertilization normally occurs in the:
a) uterine cavity b) cervix c) ampulla of the uterine tube d) ovary
Answer
c — the ampulla, the widest segment of the uterine tube. The embryo then takes three to four days to reach the uterus, which is functionally necessary: it allows the embryo to reach the blastocyst stage and the endometrium to become receptive. Delayed transport strands the embryo in the tube, which is why the ampulla is also the commonest site of ectopic pregnancy.
23.3 The countercurrent heat exchanger that helps keep the testes below core temperature is the:
a) dartos muscle b) cremaster muscle c) pampiniform plexus d) tunica vaginalis
Answer
c — the pampiniform plexus. Cool venous blood ascending from the testis surrounds the warm descending testicular artery, so heat passes from artery to vein before the blood reaches the testis. The dartos (a) and cremaster (b) also contribute to thermoregulation but by changing surface area and distance rather than by exchange. The tunica vaginalis (d) is the serous membrane derived from peritoneum.
23.4 The LH surge is triggered when estradiol:
a) falls below a threshold b) exceeds a threshold and is sustained for 36–48 hours c) is replaced by progesterone d) inhibits GnRH release
Answer
b. Above roughly 200 pg/mL sustained for 36–48 hours, estradiol's feedback reverses from negative to positive, raising GnRH pulse frequency and pituitary sensitivity to GnRH. The requirement for both a concentration threshold and a duration is what prevents spurious surges. Option d describes what estradiol does below the threshold, which is most of the cycle.
23.5 The stratum functionalis is shed each month because:
a) it has no blood supply b) its spiral arteries constrict when progesterone falls c) the myometrium contracts and expels it d) estrogen causes it to necrose
Answer
b. Spiral arteries supply the functionalis and are highly sensitive to progesterone withdrawal; when the corpus luteum dies they undergo spasmodic constriction, the tissue infarcts, and it is shed when the vessels reperfuse and rupture. The stratum basalis survives because its straight arteries are not hormone-sensitive. Option d reverses the hormone: estrogen builds the functionalis, it does not destroy it.
23.6 Spermatogenesis from spermatogonium to spermatozoon in the tubule lumen takes approximately:
a) 7 days b) 24 days c) 64–72 days d) 6 months
Answer
c — 64–72 days, plus a further 12–20 days of maturation in the epididymis before the cell can swim and bind an oocyte. This timeline is why any intervention affecting sperm production — illness, heat, a drug, a varicocele repair — takes about three months to show up on a semen analysis.
23.7 Which hormone is secreted by small growing follicles independently of gonadotropins and is therefore the best measure of ovarian reserve?
a) FSH b) estradiol c) inhibin A d) anti-Müllerian hormone
Answer
d — AMH. It is produced by granulosa cells of preantral and small antral follicles at a gonadotropin-independent stage, so it approximates a direct count of the remaining pool and is stable across the cycle. FSH (a) is a pituitary response two steps removed and fluctuates wildly in perimenopause; inhibin A (c) comes from the corpus luteum, not from the reserve.
23.8 Benign prostatic hyperplasia arises predominantly in the:
a) peripheral zone b) transition zone c) central zone d) anterior fibromuscular stroma
Answer
b — the transition zone, which surrounds the prostatic urethra, which is precisely why benign enlargement obstructs urine flow. About 70% of prostate cancers arise in the peripheral zone (a), which is the part a finger reaches on digital rectal examination and which does not usually obstruct early. One anatomical fact, four clinical consequences.
Level 2 · Comprehension
23.9 Explain why male sexual differentiation requires two active hormonal signals while female differentiation does not, and state one clinical consequence of that asymmetry.
Model answer
Every embryo begins with both duct systems present. To produce a male internal tract, one system must be destroyed and the other saved, and each requires its own signal: anti-Müllerian hormone from Sertoli cells causes the paramesonephric (Müllerian) ducts to regress, and testosterone from Leydig cells stabilizes the mesonephric (Wolffian) ducts, which would otherwise degenerate. A third signal, DHT produced from testosterone by 5α-reductase, is needed for the external genitalia and prostate. In the absence of those signals the Müllerian ducts persist and the Wolffian ducts regress by default — although the ovary itself requires an active genetic program (WNT4, RSPO1, FOXL2) rather than simply appearing.
The asymmetry means the male pathway has more steps and therefore more points of failure. Clinical consequences include androgen insensitivity syndrome, in which a 46,XY individual with functioning testes produces AMH and testosterone but has a non-functional androgen receptor: the Müllerian ducts still regress (AMH works), so there is no uterus, but the Wolffian ducts and external genitalia cannot respond to androgen, so the phenotype is female. Also acceptable: 5α-reductase deficiency, where internal male ducts form normally because testosterone acts on them, but external virilization is incomplete because DHT cannot be made.
23.10 Compare the male and female HPG axes. Identify everything that is the same and the single feature that differs, and explain why that one difference is necessary.
Model answer
The same: a three-tier axis of hypothalamus, anterior pituitary, and gonad; pulsatile GnRH, without which the pituitary desensitizes; two gonadotropins with divided labour, LH acting on the steroid-producing cell (Leydig, theca) and FSH acting on the gamete-supporting cell (Sertoli, granulosa); and two feedback signals — a steroid that reports on the hormone arm and an inhibin that selectively reports on the gamete arm. The two-cell logic of ovarian estrogen synthesis has a direct male parallel in the division of labour between Leydig and Sertoli cells.
The difference: in the female axis, estradiol's feedback changes sign above a threshold concentration sustained for 36–48 hours, switching from negative to positive and producing the LH surge. There is no equivalent in the male.
Why it is necessary: the two systems have different output requirements. The male axis must sustain continuous production of hundreds of millions of gametes per day, and continuous output is best achieved by a steady-state negative feedback controller. The female axis must release exactly one gamete at one moment, then reconfigure the entire uterus to receive an embryo. That requires an oscillator with a decisive, all-or-nothing trigger — and a threshold-dependent sign reversal is precisely how you convert a stabilizing controller into an oscillator with a switch. Like the other positive feedback loops in the body, it is made safe by a built-in endpoint: ovulation destroys the follicle producing the estradiol.
23.11 A woman's basal body temperature rises 0.4 °C after ovulation. Explain the mechanism, and explain why this is a set-point shift rather than a failure of thermoregulation.
Model answer
Progesterone, produced by the corpus luteum only after ovulation, acts on the hypothalamic thermoregulatory centre — substantially through its neurosteroid metabolite allopregnanolone acting on warm-sensitive preoptic neurons — and raises the defended temperature by 0.3–0.5 °C. It also raises resting metabolic rate by roughly 2–8%.
It is a set-point shift rather than a thermoregulatory failure because every component of the control loop is working correctly. The receptors sense accurately, the hypothalamus compares accurately, and the effectors execute accurately — they are simply defending a new target. The evidence for this is the shape of the curve: the temperature moves promptly to a new stable plateau and holds it, which is what a controller defending a new set point looks like, rather than drifting upward as it would if heat loss were failing. Exactly the same reasoning applies to fever (Chapter 1), where pyrogens raise the hypothalamic set point and the patient shivers while running a temperature of 39 °C. In both cases the correct question is not "what is broken?" but "where has the target moved?"
Level 3 · Clinical Application
23.12 A 19-year-old cross-country runner has not menstruated for nine months. Her BMI is 19.4, she trains 90 km per week, and a DEXA scan shows a lumbar spine Z-score of −2.1. Her FSH is 2.1 mIU/mL, LH 1.4 mIU/mL, and estradiol 18 pg/mL. Explain the hormone pattern, name the condition, and explain why simply prescribing an oral contraceptive would be the wrong treatment.
Model answer
The hormone pattern is low FSH, low LH, and low estradiol — a hypogonadotropic picture. This localizes the problem above the gonad: the ovary is not being stimulated, rather than failing to respond. (Contrast Amara, whose high FSH with low AMH localizes the failure to the ovary itself. Reading the tropic hormone alongside the target hormone always localizes the lesion — Chapter 16.)
The condition is functional hypothalamic amenorrhea in the context of relative energy deficiency in sport (RED-S), formerly framed as the female athlete triad. The mechanism is low energy availability — dietary intake minus exercise expenditure, normalized to fat-free mass — below roughly 30 kcal/kg FFM/day. The hypothalamus interprets this as famine: leptin, insulin, and IGF-1 fall, ghrelin and cortisol rise, and the kisspeptin gate closes, so GnRH pulse frequency falls. Without adequate GnRH pulses, LH and FSH fall, no follicle develops, and estradiol falls. Note that this is caused by the energy deficit, not by exercise or by low body fat as such; her BMI of 19.4 is unremarkable.
Why a contraceptive is the wrong treatment. The Z-score of −2.1 means her bone mineral density is well below expectations for her age — and she is 19, in the middle of the window (roughly ages 12–25) when peak bone mass is accumulated. She is not merely losing bone; she is failing to build it, and peak bone mass largely determines fracture risk for the rest of her life. An oral contraceptive would produce a monthly withdrawal bleed, which removes the clinical warning sign without correcting the underlying energy deficit, and the evidence does not show that it restores bone accrual, partly because oral ethinylestradiol suppresses hepatic IGF-1. The correct treatment is to restore energy availability — increase intake, reduce training load, or both, with dietetic and, where appropriate, psychological support — and to monitor for the return of spontaneous menses as the marker of recovery. Adequate calcium and vitamin D are supportive, not sufficient.
23.13 A 68-year-old man reports nocturia four times nightly, hesitancy, and a weak stream. He is found to have a creatinine of 2.4 mg/dL (baseline 1.0), a palpable suprapubic mass, and bilateral hydronephrosis on ultrasound. Trace the entire mechanism from prostate to kidney, and explain why his creatinine should fall rapidly after a urinary catheter is placed.
Model answer
The chain, from the top: benign hyperplasia of the prostatic transition zone, which surrounds the prostatic urethra, raises outflow resistance. The detrusor compensates by generating higher pressures and hypertrophies; a hypertrophied detrusor becomes irritable and unstable, producing the storage symptoms (frequency, urgency, nocturia) alongside the voiding symptoms (hesitancy, weak stream). Over time the bladder fails to empty completely, so post-void residual urine accumulates — this is his palpable suprapubic mass, a chronically distended bladder.
Once intravesical pressure is chronically elevated, it is transmitted retrogradely up both ureters, which is why the hydronephrosis is bilateral: a single ureteric obstruction affects one kidney, but bladder outlet obstruction affects both. Rising pressure in the collecting system is transmitted to Bowman's space, so capsular hydrostatic pressure rises. Since net filtration pressure is glomerular hydrostatic pressure minus the sum of capsular hydrostatic and blood colloid osmotic pressures — normally 55 − (15 + 30) = 10 mm Hg — a rise in capsular pressure of only 10–15 mm Hg drives NFP to zero and filtration stops. This is postrenal acute kidney injury (§26.10), and it is why his creatinine has risen from 1.0 to 2.4.
Why catheterization reverses it quickly: the lesion is purely mechanical and the tubules have not yet been destroyed. Draining the bladder immediately lowers intravesical pressure, which decompresses the ureters and the collecting systems, which lowers capsular hydrostatic pressure, which restores a positive net filtration pressure. Filtration resumes within hours and the creatinine typically falls over one to three days. Two things to anticipate: a post-obstructive diuresis, sometimes several litres a day, as retained solute and water are excreted and damaged tubules temporarily fail to concentrate — requiring careful fluid and electrolyte replacement — and the possibility of incomplete recovery if the obstruction has been present long enough to cause interstitial fibrosis.
23.14 A 27-year-old woman has had irregular cycles since menarche, hirsutism, a BMI of 31, and has been trying to conceive for 18 months. Her testosterone is mildly elevated, LH:FSH ratio 2.8:1, AMH 7.2 ng/mL, and ultrasound shows 28 follicles of 2–8 mm in each ovary. Explain the full mechanism, and explain why letrozole rather than more FSH is first-line for ovulation induction.
Model answer
This is polycystic ovary syndrome by the Rotterdam criteria: she meets all three (oligo-ovulation, clinical and biochemical hyperandrogenism, and polycystic ovarian morphology).
The mechanism begins outside the ovary. Insulin resistance — present in a majority of women with PCOS, and worsened but not caused by her adiposity — produces compensatory hyperinsulinemia. That hyperinsulinemia has three effects that all push the same way: (1) theca cells remain fully insulin-sensitive for steroidogenesis even while muscle and liver are resistant, so insulin directly amplifies LH-driven androgen production; (2) insulin suppresses hepatic sex hormone-binding globulin, so a given total testosterone yields much more free, bioavailable testosterone; and (3) altered GnRH pulse frequency raises the LH:FSH ratio, which drives the theca side hard while relatively starving the granulosa side of the FSH it needs for aromatase.
The consequence is a large pool of small antral follicles — hence her AMH of 7.2 ng/mL and 28 follicles per ovary — that arrest at 2–8 mm because no single follicle can achieve the FSH dominance required for selection. High AMH itself contributes, by reducing granulosa sensitivity to FSH. No dominant follicle means no ovulation, no corpus luteum, no progesterone, and therefore both infertility and an endometrium exposed to unopposed estrogen.
Why letrozole rather than gonadotropins. Letrozole is an aromatase inhibitor: it blocks conversion of androgens to estradiol, so circulating estradiol falls, so estrogen's negative feedback on the pituitary is reduced, so endogenous FSH rises — and the rise is transient, because as the dominant follicle grows and estradiol recovers, feedback is restored and the remaining follicles are allowed to atrese normally. In other words, letrozole restores the selection mechanism rather than overriding it. Injected FSH, by contrast, holds the whole cohort above threshold and produces multiple mature follicles, with a substantially higher risk of multiple pregnancy and of ovarian hyperstimulation syndrome — a real hazard in exactly this population, because they have so many recruitable follicles. Letrozole also outperforms clomiphene for live birth in PCOS and, unlike clomiphene, does not block estrogen receptors in the endometrium and cervical mucus. Weight loss and metabolic therapy address the top of the cascade and can restore ovulation without any of these drugs.
Level 4 · Integration and Synthesis
23.15 Amara, Nia, and Adwoa are three women at 45, 24, and 78. Construct a single argument that connects all three of their skeletal states to one hormone, using material from this chapter and Chapter 6, and identify the one intervention that would help most at each age.
Model answer
The unifying hormone is estradiol, and the unifying variable is bone mass across the lifespan, which is best thought of as a single curve: a build phase, a plateau, and a loss phase.
Nia, 24 — the build phase. Roughly 90% of adult bone mass is laid down by 18 and peak bone mass is reached in the mid-twenties. Estradiol restrains osteoclasts (raising osteoprotegerin, lowering RANKL) and supports osteoblast survival; it is also what closes the epiphyses. Nia's regular ovulatory cycles, confirmed by her luteal temperature rise, mean her estradiol exposure is normal and her peak bone mass is being achieved. Had she instead developed functional hypothalamic amenorrhea from low energy availability — the RED-S pattern — she would have entered adulthood with a permanently lower ceiling, because bone not built in this window is not recoverable later. Best intervention at 24: maintain energy availability and cycle regularity, plus weight-bearing and impact loading, which is exactly the mechanical stimulus that Chapter 6's Wolff's law predicts.
Amara, 45 — the inflection. She is entering the transition, with FSH 24 and AMH 0.3. Once her final menstrual period passes, trabecular bone will be lost at roughly 2% per year for the first five to eight years, then more slowly. Vertebrae and the distal radius go first because they are trabecular-rich and have the highest surface-to-volume ratio, so a change in remodeling balance bites there first. She has additional risks stacked on top: chronic kidney disease with a PTH of 88 pg/mL and reduced calcitriol activation (Chapter 26), and metabolic acidosis with a bicarbonate of 21 mEq/L, which is buffered partly by bone. Best intervention at 45: baseline bone density measurement now rather than at 65, correction of vitamin D and the renal mineral abnormalities, resistance training, and an explicit decision about whether her symptoms warrant hormone therapy, which is the most effective preventive for post-menopausal bone loss in an appropriate candidate.
Adwoa, 78 — the consequence. She had her final menstrual period at 49 and has had nearly three decades of estrogen-deficient remodeling, on top of the age-related decline in osteoblast function, reduced calcitriol activation by an aging kidney (§26.8), reduced intestinal calcium absorption, and sarcopenia that reduces both mechanical loading and protective reflexes. Her osteoporosis is the integral of Amara's curve. Best intervention at 78: fracture prevention rather than bone building — antiresorptive or anabolic pharmacotherapy, adequate protein, vitamin D and calcium, balance and strength training to prevent falls, and a review of medications that cause postural hypotension.
The single argument: all three women are at different points on one estradiol-dependent curve, and the intervention that helps most at each age is determined by which phase of the curve they are in. It is also the clearest example in the book of why menopause is a systemic endocrine event rather than a reproductive one.
23.16 Argue for or against: "The reproductive system is the only organ system whose failure does not threaten the life of the individual, and it should therefore be taught last." Use at least four specific mechanisms from this chapter.
Model answer
A strong answer grants the first clause and rejects the conclusion.
Granting the premise: it is true that gonadal failure is not acutely lethal. A person without gonads lives; a person without kidneys, lungs, or a heart does not. The reproductive system is the only system whose purpose is external to the individual — it maintains the species at some cost to the individual, which is why it is the system most readily sacrificed under energy stress (RED-S, §27.9) and the only one that switches off in mid-life by design.
Rejecting the conclusion, with four mechanisms:
- Bone. Estradiol is the principal restraint on osteoclasts in both sexes and the hormone that closes the epiphyses. Its loss produces post-menopausal osteoporosis at ~2% of trabecular bone per year, and hip fracture carries roughly 20–30% one-year mortality. Gonadal failure kills, it just does so twenty years later and through a different organ.
- Vasculature and lipids. Estrogen raises endothelial nitric oxide synthase, hepatic LDL receptor expression, and apoA-I. Losing it worsens LDL, HDL, arterial stiffness, and endothelial function simultaneously — Amara's exact eighteen-month trajectory. Cardiovascular disease is the leading cause of death in women, and its epidemiology has a menopausal inflection.
- Metabolism. Estrogen loss redistributes fat from gluteofemoral to visceral depots, worsening insulin resistance; and in the other direction, insulin resistance drives the hyperandrogenism of PCOS through an ovary that remained insulin-sensitive. Causation runs both ways between the gonad and metabolic disease.
- Urinary tract. Estrogen maintains vaginal glycogen, lactobacilli, and acidity, and supports urethral and trigonal epithelium. Its loss raises vaginal pH and the rate of recurrent urinary tract infection — a genuine hazard in a patient with reduced GFR.
A fifth, if wanted: BPH, in which a reproductive accessory gland obstructs the urinary tract and can produce postrenal acute kidney injury and, untreated, permanent renal damage.
The synthesis: the premise confuses acute survival with health. The gonads are endocrine glands whose products maintain at least five non-reproductive systems, so teaching them last — after the systems they regulate — is defensible only as ordering, not as ranking. Indeed this book places the chapter late for exactly the right reason: you need bone, vessels, lipids, kidney, and metabolism already in hand before the systemic actions of the gonadal steroids can be understood at all.
Concept Map to Complete
Copy this onto blank paper and fill every bracket from memory before checking the chapter.
BIPOTENTIAL GONAD + BOTH DUCT SYSTEMS
│
┌───────────────────────┴───────────────────────┐
[ ____ ] PRESENT [ ____ ] ABSENT
│ │
┌─────┴─────┐ ovary; [ _______ ]
SERTOLI LEYDIG ducts persist →
→ [ ___ ] → [ __________ ] [ ___ ][ ___ ][ ___ ]
→ [ ___ ] → [ ___ ] ducts saved
ducts regress │
5α-reductase → [ ___ ] → external genitalia + prostate
══════════════════════════════════════════════════════════════════
THE FEMALE CYCLE
FSH rises when [ _______ ] and [ _________ ] fall (day 1–5)
↓
cohort recruited → DOMINANT follicle selected by [ ________ ] the
↓ resource its rivals need
estradiol rises → crosses [ ____ ] pg/mL for [ __ ] hours
↓
FEEDBACK SIGN [ ________ ] → ★ [ ____ ] SURGE ★
↓
OVULATION at [ __ ] hours after the surge begins
↓
CORPUS LUTEUM → [ ____________ ] → uterine [ _________ ] phase
↓ → raises hypothalamic [ ________ ] by [ ___ ] °C
no hCG → luteolysis at day [ __ ] → progesterone FALLS
↓
[ ______ ] arteries constrict → functionalis infarcts → MENSTRUATION
[ ______ ] arteries survive → [ _______ ] regenerates
══════════════════════════════════════════════════════════════════
PERIMENOPAUSE (why FSH is 24 mIU/mL)
fewer small growing follicles → less [ ________ ] → FSH is
[ ____________ ] → FSH RISES. Confirm with [ ____ ], which is
[ __________________ ]-independent.
Estrogen loss then costs: bone [ __ ] LDL [ __ ] HDL [ __ ]
nitric oxide [ __ ] visceral fat [ __ ]
Lab / Self-Exploration
- Chart a basal body temperature curve. Take an oral temperature with a digital thermometer immediately on waking, before sitting up, at the same time each morning for one full cycle. Plot it. You should see the biphasic pattern of Figure 27.6, panel E — a follicular baseline and a luteal plateau 0.3–0.5 °C higher. Mark the day the shift occurred and note that it tells you ovulation happened one to two days earlier.
- Track resting heart rate against the same chart. Most fitness trackers record it. Overlay it on the temperature curve and see whether your own luteal rise resembles Nia's five beats per minute.
- Palpate the landmarks you can palpate. Find the pubic symphysis and the anterior superior iliac spines, and locate the line between them along which the inguinal canal runs — the route taken by the descending testis and by the round ligament of the uterus. Note that the same anatomical tunnel explains hernias in both sexes.
- Read a semen analysis reference range. Look up the current WHO lower reference limits for volume, concentration, total count, motility, and normal forms. Then calculate what proportion of a single ejaculate would still exceed the total-count threshold if concentration were halved. Notice how much redundancy the system carries.
- Do the timeline arithmetic. If spermatogenesis takes 70 days and epididymal transit another 14, calculate the earliest date on which a semen analysis could show the effect of an intervention started today. Then explain to someone why fertility studies always wait three months.
- Reconstruct the cycle from a blank sheet. Draw the 28-day axis and plot, from memory, FSH, LH, estradiol, progesterone, follicle stage, endometrial thickness, and basal body temperature. Then check against Figure 27.6. The panels you get wrong are the ones to restudy — and for most students it is the FSH curve, because it moves twice for two different reasons.
Key Terms
acrosome · The enzyme-filled cap over the sperm nucleus, formed from the Golgi apparatus during spermiogenesis; its enzymes allow penetration of the oocyte's coverings.
anti-Müllerian hormone (AMH) · Secreted by fetal Sertoli cells to cause regression of the paramesonephric ducts; in adult women, secreted by small growing follicles and used as the best measure of ovarian reserve.
antral (vesicular) follicle · A follicle containing a fluid-filled antrum; the first gonadotropin-dependent stage.
blood-testis barrier · Tight junctions between adjacent Sertoli cells that isolate post-meiotic germ cells from the immune system.
bulbourethral (Cowper's) glands · Paired glands secreting alkaline pre-ejaculatory mucus.
corpus luteum · The luteinized remnant of the ovulated follicle; secretes progesterone, estradiol, and inhibin A for 14 ± 2 days unless rescued by hCG.
corpus albicans · The fibrous scar left after the corpus luteum regresses.
cremaster muscle · Skeletal muscle of the spermatic cord that raises the testes toward the body wall.
cryptorchidism · Failure of testicular descent; impairs spermatogenesis and raises germ cell tumour risk because the testis sits at core temperature.
dartos muscle · Smooth muscle of the scrotal wall that wrinkles the skin to reduce heat loss.
dihydrotestosterone (DHT) · Testosterone converted by 5α-reductase; responsible for external genitalia, prostate growth, and male-pattern hair.
ductus (vas) deferens · The 45 cm muscular duct carrying sperm from epididymis to ejaculatory duct; the site of vasectomy.
endometriosis · Endometrial-like tissue outside the uterus; estrogen-responsive, locally aromatase-expressing, and a cause of pain and infertility.
endometrium · The uterine lining, divided into a shed stratum functionalis and a permanent stratum basalis.
epididymis · Six metres of coiled duct in which sperm mature over 12–20 days and are stored.
estradiol · The principal estrogen; drives follicular growth and endometrial proliferation, and acts systemically on bone, endothelium, liver, adipose tissue, and brain.
follicle-stimulating hormone (FSH) · Pituitary gonadotropin acting on granulosa cells (aromatase, inhibin B) and Sertoli cells (androgen-binding protein, spermatogenic support).
functional hypothalamic amenorrhea · Loss of menses from suppressed GnRH pulsatility, most often caused by low energy availability; reversible, but with lasting skeletal cost.
gonadotropin-releasing hormone (GnRH) · Pulsatile hypothalamic hormone driving LH and FSH release; continuous exposure desensitizes the pituitary.
inhibin B · Gonadal peptide that selectively inhibits FSH; secreted by Sertoli cells and by granulosa cells of small antral follicles. Its fall is the first event of perimenopause.
Leydig (interstitial) cells · Testosterone-producing cells between the seminiferous tubules; LH-responsive.
LH surge · The tenfold rise in luteinizing hormone triggered by estradiol's switch to positive feedback; causes ovulation about 36 hours later.
menopause · Twelve consecutive months of amenorrhea without another cause; median age 51.
myometrium · The three-layered smooth muscle wall of the uterus.
oogenesis · Production of the ovum; begins before birth, arrests in prophase I and again in metaphase II, and yields one gamete plus polar bodies per primary oocyte.
ovarian reserve · The remaining pool of primordial and small growing follicles; measured by AMH and antral follicle count.
pampiniform plexus · The venous network around the testicular artery that acts as a countercurrent heat exchanger; its failure is a varicocele.
perimenopause · The menopausal transition, characterized by rising FSH, falling AMH, erratic estradiol, and increasingly irregular cycles.
polycystic ovary syndrome (PCOS) · Oligo-ovulation with hyperandrogenism and polycystic ovarian morphology, driven by insulin resistance acting on a still-insulin-sensitive theca cell.
progesterone · The dominant luteal hormone; produces the secretory endometrium, thickens cervical mucus, and raises the hypothalamic temperature set point by 0.3–0.5 °C.
prostate · Accessory gland supplying 25–30% of semen; its transition zone hypertrophies benignly and its peripheral zone is where most cancers arise.
prostate-specific antigen (PSA) · Prostatic protease that liquefies the semen coagulum; used clinically as a tumour marker, and halved by 5α-reductase inhibitors.
seminal vesicles · Paired glands supplying 60–70% of semen volume, including fructose and prostaglandins.
seminiferous tubule · The site of spermatogenesis; germ cells mature from basement membrane toward the lumen.
Sertoli (sustentacular) cell · The supporting cell of the seminiferous tubule; forms the blood-testis barrier and secretes androgen-binding protein, inhibin B, and fetal AMH.
spermatogenesis · Production of sperm from spermatogonia; 64–72 days, continuous from puberty.
spermiogenesis · The non-dividing remodeling of a spermatid into a spermatozoon.
spiral arteries · Progesterone-sensitive coiled arteries supplying the stratum functionalis; their spasm on progesterone withdrawal causes menstruation.
SRY · The Y-chromosome gene whose product directs the bipotential gonad to become a testis.
straight arteries · Hormone-insensitive arteries supplying the stratum basalis, which therefore survives menstruation.
testosterone · The principal androgen; acts directly, and through DHT and estradiol, on ducts, muscle, marrow, bone, skin, and brain.
tunica albuginea · Dense fibrous capsule; of the testis, it divides the organ into lobules; of the corpora cavernosa, it permits veno-occlusion and rigidity.
two-cell, two-gonadotropin model · LH-driven theca cells make androstenedione; FSH-driven granulosa cells aromatize it to estradiol. Neither cell can make estrogen alone.
uterine (fallopian) tube · The 10 cm duct whose ampulla is the site of fertilization; transports by cilia, peristalsis, and fimbrial sweeping.
zona pellucida · The glycoprotein coat around the oocyte; a key histological landmark and the structure sperm must penetrate.
Next: Chapter 28 · Pregnancy and Human Development — where Nia becomes pregnant, the corpus luteum is rescued rather than allowed to die, and every system in this book is asked to support two people at once.